US4076831A - Pyrano[3,4-b]-indole derivatives, pharmaceutical compositions and methods of use - Google Patents
Pyrano[3,4-b]-indole derivatives, pharmaceutical compositions and methods of use Download PDFInfo
- Publication number
- US4076831A US4076831A US05/749,931 US74993176A US4076831A US 4076831 A US4076831 A US 4076831A US 74993176 A US74993176 A US 74993176A US 4076831 A US4076831 A US 4076831A
- Authority
- US
- United States
- Prior art keywords
- sub
- acetic acid
- methyl
- indole
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime, expires
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/76—Benzo[c]pyrans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- H—ELECTRICITY
- H10—SEMICONDUCTOR DEVICES; ELECTRIC SOLID-STATE DEVICES NOT OTHERWISE PROVIDED FOR
- H10D—INORGANIC ELECTRIC SEMICONDUCTOR DEVICES
- H10D10/00—Bipolar junction transistors [BJT]
Definitions
- This invention relates to novel indole derivatives, to processes for their preparation and to intermediates used in these processes.
- the indole derivatives of this invention have been found to exhibit interesting and useful pharmacodynamic properties without eliciting undesirable side effects. Notable attributes of this effect are antiinflammatory and analgesic activities. In addition the compounds of this invention exhibit antibacterial and antifungal properties.
- the indole derivatives of this invention are characterized by having a pyrano[3,4-b]indole or thiopyrano[ 3,4-b]indole nucleus bearing a substituent at positon 1, said substituent incorporating an acid, ester or amide function therein.
- R 1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl and 2-thienyl
- R 2 , R 3 , R 4 and R 5 are the same or different and are each selected from the group consisting of hydrogen and lower alkyl
- R 6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, phenyl, nitro, halo, mercapto, lower alkylthio, trifluoromethyl, amino and sulfamoyl
- R 7 is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl
- X is selected from the group consisting of oxy and thio
- Y is selected from the group consisting of carbonyl, ##STR2## which each of R 8
- R 6 represents from one to four substituents, which may be present simultaneously, at positions 5,6,7 and 8 thereof.
- R 6 represents from one to four substituents, which may be present simultaneously, at positions 5,6,7 and 8 thereof.
- R 6 may also include additional definitions, for example, mercapto, lower alkylthio, trifluoromethyl and other halo(lower)alkyls, amino and sulfamoyl, provided that any two such substituents do not interfere with each other.
- the indole derivatives of this invention are represented also be general formula Ia ##STR3## in which R 1 , R 2 , R 3 , R 4 , R 5 , R 7 , X, Y and Z are as defined in the first instance and R 6a , R 6b , R 6c and R 6d are the same or different and each is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, phenyl, nitro, halo, mercapto, lower alkylthio, trifluoromethyl, amino and sulfamoyl.
- the indole derivatives of this inventon of formula I are prepared by reacting a compound of the formula ##STR4## in which R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined in the first instance and X' is hydroxy or mercapto with a compound of formula ##STR5## in which R 1 , Y and Z are as defined in the first instance, in the presence of an acid catalyst.
- lower alkyl as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, 2-methylpentyl and the like.
- lower alkenyl as used herein contemplates both straight and branched chain alkenyl radicals containing from two to six carbon atoms and includes vinyl, allyl, 1-propenyl, methallyl, 2-ethyl-3-butenyl and the like.
- lower alkynyl as used herein contemplates both straight and branched chain alkynyl radicals containing from two to six carbon atoms and includes ethynyl, propargyl, 1,1-dimethylpropargyl and the like.
- lower cycloalkyl as used herein contemplates saturated cyclic hydrocarbon radicals containing from three to six carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl and the like.
- lower alkoxy as used herein contemplates both straight and branched chain alkoxy radicals containing from one to four carbon atoms and includes methoxy, ethoxy, isopropoxy and the like.
- lower alkanoyloxy contemplates both straight and branched chain alkanoyloxy radicals containing from two to six carbon atoms and includes acetoxy, propionyloxy, hexanoyloxy and the like.
- halo as used herein contemplates halogens and includes fluorine, chlorine, bromine and iodine.
- alkylamino and dialkylamino contemplates one to six carbon atoms for each alkyl group of such a radical and includes methylamino, n-hexylamino, dimethylamino, diethylamino and the like.
- the indole derivatives of formula I in which Z is hydroxy, the acid compounds of this invention form addition salts with suitable inorganic and organic bases.
- suitable bases to form these salts include, for example, the hydroxides, lower alkoxides, carbonates and bicarbonates of sodium, potassium, calcium and magnesium, as well as the bases, ammonia, triethylamine, benzylamine and the like.
- the addition salts thus obtained are the functional equivalents of the parent acid compound in respect to their therapeutic use. Hence, these addition salts are included within the scope of this invention and are limited only by the requirement that the bases employed in forming the salts be pharmaceutically acceptable.
- the useful antiinflammatory and analgesic activities of the indole derivatives of this invention may be demonstrated in standard pharmacologic tests, for example, the tests described by R. A. Turner in “Screening Methods in Pharmacology", Academic Press, New York and London, 1965, pp. 152-163 and pp. 100-117, respectively,
- the antiinflammatory activity of the compounds of this invention may be readily demonstrated in a modification of the Freund's adjuvant test, the adjuvant induced acute edema test as described by J. R. Boissier, et al., Therapie, 25, 43 (1970). This test is known to correlate well with data derived from clinical results with humans. Boissier et al. have demonstrated this correlation with such clinically active compounds as phenylbutazone, mefenamic acid, indomethacin, aspirin, hydrocortisone and prednisolone.
- a substantial antiinflammatory effect for the compounds listed below is demonstrable at oral doses of 100 mg/kg or less in this acute edema test.
- male rats are treated with the test compound one hour before the injection of Freund's adjuvant into the paw (day 0). The rats are then treated with the same dose of the test compound for the next three days.
- the antiinflammatory effect of the test compound is measured by the reduction of pedal inflammation, see Turner cited above, and expressed as a percent inhibition from adjuvant injected control rats on day 3.
- the present indole derivatives of this invention When employed as antiinflammatory and analgetic agents in warm-blooded animals, e.g., rats, they may be administered orally, alone or in dosage forms, i.e., capsules or tablets, combined with pharmacologically acceptable excipients, such as starch, milk sugar and so forth. They may also be administered orally in the form of solutions in suitable vehicles such as vegetable oils.
- the dosage of the indole derivatives of this invention will vary with the particular compound chosen and form of administration. Furthermore, it will vary with the particular host under treatment. Generally, the compounds of this invention are administered at a concentration level that affords protective effects without any deleterious side effects. These antiinflammatorily-analgesically effective concentration levels are usually obtained within a therapeutic range of 1.0 mg to 500 mg/kg per day, with a preferred range of 10 to 100 mg/kg per day.
- the indole derivatives of this invention also exhibit utility as antibacterial agents against a number of gram-positive and gram-negative microorganisms, such as, Staphylococcus pyrogenes, both penicillin sensitive and penicillin resistant, Streptococcus faecalis, Escherichia coli, Aerobacter aerogenes, Salmonella pullorum, Pseudomonas aerugenosa, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumoniae and Serratia marcescens and as antifungal agents against a number of pathogenic fungi such as, Candida albicans, Microsporum gypseum and Trichophyton granulosum, in standard tests for antibacterial and antifungal activity, such as those described in "Antiseptics, Disinfectants, Fungicides and Sterilization", G. F. Reddish, Ed., 2nd ed., Lea and Febiger, Philadelphia, 1957 or by D
- the comounds of this invention When the comounds of this invention are employed as antibiotic or antifungal agents in warm-blooded animals, e.g. rats, they may be administered alone or in combination with pharmacologically acceptable carriers.
- the proportion of the compound is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice. For example, they may be administered orally in solid form containing such excipients as starch, milk sugar, certain types of clay and so forth. They may also be administered orally in the form of solutions or they may be injected parenterally. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
- the dosage of the present therapeutic agents as antibiotic or antifungal agents will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
- the compounds of this invention are most desirably administered at a concentration level that will generally afford antibacterially or antifungally effective results without causing any harmful or deleterious side effects and preferably at a level that is in a range of from about 1.0 mg. to about 1000 mg. per kilo per day, although as aforementioned variations will occur. However, a dosage level that is in the range of from about 10 mg. to about 500 mg. per kilo per day is most desirably employed in order to achieve effective results.
- the agent may be employed topically.
- they may be formulated in the form of solutions, creams, or lotions in pharmaceutically acceptable vehicles containing 0.1-5 percent, preferably 2 percent, of the agent and may be administered topically to the infected area of the skin.
- the antibacterial properties of the compounds of this invention may be utilized for washing equipment in hospitals, homes and farms, instruments used in medicine and bacteriology, clothing used in bacteriological laboratories, and floors, walls and ceiling in rooms in which a background free of gram-positive and gram-negative microorganisms, such as those listed above, is desired.
- the compounds of this invention may be formulated in a number of compositions comprising the active compound and an inert material.
- the compounds of formula I of this invention may be employed in concentrations as low as 500 p.p.m., from a practical point of view, it is desirable to use from about 0.10% by weight, to about 5% by weight or more.
- the formulations that may be used to prepare antiseptic wash solutions of the compounds of this invention are varied and may readily be accomplished by standard techniques, see for example, "Remington's Practice of Pharmacy", E. W. Martin et al., Eds., 12th ed., Mack Publishing Company, Easton, Penn., 1961, pp. 1121 - 1150.
- the compounds may be made up in stock solutions. They can also be formulated as suspensions in an aqueous vehicle. These make useful mixtures for decontaminating premises.
- aqueous vehicles containing emulsifying agents, such as sodium lauryl sulfate, and relatively high concentrations, e.g., up to about 5% by weight, of the compounds may be formulated by conventional techniques.
- a typical antiseptic preparation useful for disinfecting floors, walls, ceiling, and articles in a contaminated room may be prepared by adding 5 to 25 g. of N,N,1-trimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide to a mixture of 150 to 300 g. of polyethylene glycol 1540 and 150 to 300 g. of polyethylene glyol 300. The resulting mixture is stirred while a solution of 1 to 10 g. of sodium lauryl sulfate in 300 to 400 ml. of water is added portionwise. The article to be disinfected is coated or immersed in the preparation for a prolonged time, for example, one hour, and then rinsed with sterile water.
- the phenylhydrazines of formula III are either known or may be prepared according to known methods.
- a convenient method involves the diazotization of the appropriately substituted aniline to give the corresponding diazo derivative.
- the latter compound is then reduced with stannous chloride or sodium sulfite to give the corresponding phenylhydrazine, see L. F. Fieser and M. Fieser, "Advanced Organic Chemistry", Reinhold Publishing Corporation, New York, 1961, p. 734.
- hydroxyaldehydes of formula IV are either known, see for example, "Rodd's Chemistry of Carbon Compounds," S. Coffey, Ed., Vol. I d, 2nd ed., Elsevier Publising Co., Amsterdam, 1965, pp. 44 - 49, or they may be prepared according to known methods.
- a convenient method involves reduction of an appropriate lactone of formula ##STR8## with bis-(3-methyl-2-butyl)borane, H. C. Brown and D. B. Bigley J. Am. Chem. Soc., 83, 486 (1961), diisobutyl aluminum hydride, L. I. Zakharkkin and I. M.
- the starting materials of formula II in which R 2 , R 3 , R 4 and R 7 are hydrogen and X' is hydroxy may be prepared by lithium aluminum hydride reduction, N. G. Gaylord, "Reduction with Complex Metal Hydrides", Interscience Publishers, Inc., New York, 1956, pp. 332 - 370, of compounds of formula V described by T.-Y. Shen, U.S. Pat. No. 3,161,654, Dec. 15, 1964: ##STR9## wherein R 15 is lower alkyl and R 5 and R 6 are as defined in the first instance.
- the starting materials of formula II in which X' is mercapto and R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are as defined in the first instance may be obtained by the following process:
- the appropriate 3-(2-bromoethyl)-indole derivative is treated with sodium or potassium thiosulfate to afford the corresponding sodium or potassium ⁇ -(3-indolyl)ethyl thiosulfate derivative, respectively, which on treatment with strong alkali for example, sodium or potassium hydroxide, is transformed into the corresponding bis-[ ⁇ -(3-indolyl)ethyl]disulfide derivative. Reduction of the latter compound with lithium aluminum hydride gives the desired compounds of formula II.
- the benzyloxy group is removed by hydrogenation, in the presence of a catalyst, for example, 10% palladium on carbon, to afford the corresponding compound of formula I in which R 6 is hydroxy.
- a catalyst for example, 10% palladium on carbon
- the latter may be converted if desired to the corresponding compound of formula I in which R 6 is lower alkanoyloxy by conventional means, for example, by treatment with the appropriate lower alkanoic anhydride preferably in the presence of pyridine.
- similar use of the starting materials of formula II in which X' is hydroxy and R 6 is benzyloxy to obtain the corresponding compound of formula I in which R 6 is hydroxy or lower alkanoyloxy is preferred.
- a solvent as a reaction medium. Any solvent inert to the reaction conditions may be used. Suitable solvents include benzene, toluene, diethyl ether, dioxan, tetrahydrofuran, methylene dichloride, carbon tetrachloride and the like. Benzene and tetrahydrofuran are especially convenient and practical for this use.
- a variety of suitable acid catalysts may be used for this condensation, for example, the type of catalyst used in a Friedel-Crafts Reaction, i.e.
- p-Toluenesulfonic acid, boron trifluoride and phosphorus pentoxide are included among the preferred acid catalysts.
- the amount of acid catalyst used is not especially critical and may range from 0.01 molar equivalents to 100 molar equivalents; however, a range of from 0.1 to 10 molar equivalents is generally preferred.
- the time of the reaction may range from 10 minutes to 60 hours, with the preferred range being from one-half to 24 hours.
- the temperature of the reaction may range from -20° C. to the boiling point of the reaction mixture. Preferred temperature ranges include 20° to 120° C.
- ⁇ -, ⁇ -, ⁇ - and ⁇ - ketoacids and -ketoesters of formula VI are either known, for example, ethyl pyruvate, levulinic acid, ethyl ⁇ , ⁇ -dimethylacetoacetate, ⁇ , ⁇ -dimethyllevulic acid and benzoylacetic acid or they may be prepared by known methods described in general organic chemistry textbooks. For example, a comprehensive review on the properties and preparation of such ⁇ -, ⁇ -, ⁇ - and ⁇ - ketoacids and -ketoesters may be found in "Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1d, pp. 226 - 274.
- the acid compounds of formula I in which Z is hydroxy and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are as defined in the first instance may be prepared by the following process: ##STR12## in which Y' is CH 2 , C(R 8 )(R 9 )CH 2 , C(R 8 ) (R 9 )C(R 10 )(R 11 )CH 2 or C(R 8 )R 9 )C(R 10 )(R 11 )C(R 12 )(R 13 )CH 2 , R 17 is hydrogen or lower alkyl, Z is hydroxy and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are as defined in the first instance.
- a starting material of formula II is condensed with an acylated ketoalcohol (VIII) in the presence of a suitable acid catalyst according to the conditions described above for the condensation (II + VI ⁇ VII).
- the ketoalcohol lower alkyl esters are either known, for example, acetonyl acetate or 5-acetoxypentan-2-one, or may be prepared by known methods, for instance, see “Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1d, pp. 49 - 54. In this manner the condensation product of general formula IX is obtained.
- aldehyde XI may be converted to the desired acid compounds of formula I by a variety of oxidizing agents, including silver oxide, alkaline permanganate, hydrogen peroxide, peracids and the like. In this case we prefer to use silver oxide according to the method of M. Delepine and P. Bonnet, Compt. rend., 149,39 (1909).
- the amide compound of this invention of formula I in which Z is amino, lower alkylamino, di(lower)alkylamino and phenylamino and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are as defined in the first instance, may be prepared from their corresponding acid compounds of formula I (compounds of formula VII in which R 16 is hydrogen, described above) by treatment of the latter compounds with a lower alkyl chloroformate, preferably ethyl chloroformate, in the presence of triethylamine, affording the corresponding mixed anhydride, which is converted by treatment with the appropriate amine, such as ammonia, aniline or a suitable alkylamine or dialkylamine, to the desired amide compound of formula I.
- a lower alkyl chloroformate preferably ethyl chloroformate
- these amides of formula I may be prepared from the corresponding esters of formula I (compounds of formulae VII, in which R 16 is lower alkyl, described above) by treatment of the latter compounds with the appropriate amine according to known methods, for example, see A. L. J. Beckwith in "The Chemistry of Amides", J. Zalicky, Ed., Interscience Publishers, New York, 1970, pp. 96 - 105.
- the amide compounds of formula I in which Z is amino, lower alkylamino, di(lower)alkylamino, and phenylamino and R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X and Y are as defined in the first instance, may be prepared by the condensation of an appropriate starting material of formula II with an appropriate ⁇ -, ⁇ -, ⁇ - or ⁇ -ketoamide in the presence of a suitable acid catalyst according to the conditions described above for the condensation (II + VI ⁇ VII).
- ketoamides required for this condensation are either known, for example, pyruvamide or ⁇ , ⁇ -dimethylacetoacetamide, or they may be prepared by known methods, for instance, see “Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1d, pp. 226 - 274.
- alkylated acid and ester compounds of this invention of formula I in which R 7 is lower alkyl or lower alkenyl and Z is hydroxy or lower alkoxy are prepared readily from the above described, corresponding acid or ester compounds of formula I in which R 7 is hydrogen.
- This conversion involving the N-alkylation of the indolic nitrogen is effected by treatment of the latter compounds with an appropriate lower alkyl or lower alkenyl halide in an inert solvent in the presence of an acid acceptor.
- Preferred conditions for effecting this conversion include the use of sodium hydride as an acid acceptor and tetrahydrofuran as the inert solvent.
- N-alkylated amide compounds of formula I in which R 7 is lower alkyl or lower alkenyl and Z is amino, lower alkylamino, di(lower)alkylamino or phenylamino are preferably prepared by either treatment of the N-alkylated acid compounds of formula I, described above, with a lower alkyl chloroformate followed by treatment with the appropriate amine, or treatment of the N-alkylated ester compounds of formula I, described above, with an appropriate amine, in the manner described previously for the preparation of the amide compounds of formula I in which R 7 is hydrogen.
- N-alkylated amide compounds of formula I in which R 7 is lower alkyl or lower alkenyl and Z is di(lower)alkylamino by N-alkylation of the corresponding compounds of formula I in which R 7 is hydrogen is considered to be a process which would be functionally equivalent to the process embodied herein for the preparation of these compounds.
- the acid and ester compounds of formula Ia in which R 6a , R 6b , R 6c , R 6d and R 7 are as defined in the first instance, Z is hydroxy or lower alkoxy, and R 1 , R 2 , R 3 , R 4 , R 5 , X and Y are as defined in the first instance, are readily prepared by the condensation (IIa+VI ⁇ VIIa), illustrated below, according to the conditions described previously for the condensation (II+VI ⁇ VII).
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 6c , R 6d , R 7 , X, Y and R 16 are as defined in the first instance.
- the amide derivatives of formula Ia are prepared by the condensation of an appropriate starting material of formula IIa with an appropriate ⁇ -, ⁇ -, ⁇ - or ⁇ -ketoamide in the presence of a suitable acid catalyst according to the conditions described previously for the condensation (II+VI ⁇ VII).
- Ethyl acetoacetate (23.4 g., 0.18 moles) is added to a solution of the starting material of formula II, tryptophol (10.0 g., 0.06 moles). in 200 ml. of benzene. After standing for 10 minutes, p-toluenesulfonic acid (1.3 g.) and about 5 g. of hydrated alkali-aluminum silicate (Molecular Sieves No. 4) are added. The mixture is subjected to reflux for thirty minutes, 600 mg. more of p-toluenesulfonic acid is added and refluxing continued for 21/2 hours.
- the molecular sieves are collected and the benzene solution washed successively with 5% sodium bicarbonate and water, dried over sodium sulfate, and evaporated under reduced pressure to dryness affording an oil.
- the oil is subjected to chromatography on silica gel. Elution with 5% ether in benzene yields the ester, 1-methyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid ethyl ester, as an oil, ⁇ max CHCl .spsb.3 1715 cm -1 .
- a mixture of the starting material of formula II, tryptophol (500 mg.) levulinic acid (580 mg.), 75 ml. of benzene, 1.7 g. of phosphorus pentoxide and about 0.5 g. of diatomaceous earth (Celite) is stirred magnetically at room temperature for 15 minutes and then at 70° C. for 11/2 hr.
- the reaction mixture is filtered.
- the filtrate is washed three times with 5N NaOH; the combined aqueous phase is washed twice with ether and then rendered acidic with cold 50% HCl.
- the aqueous phase is extracted with chloroform.
- the chloroform extract is dried (Na 2 SO 4 ) and evaporated to dryness.
- Indole-3-ethanethiol (1.5 g.) and methyl acetoacetate are mixed with 50 ml. of benzene and the solution heated for 30 min. (bath temperature 70°-80° C.).
- p-Toluenesulfonic acid (0.15 g.) is added and the reaction mixture is subjected to reflux and stirring for 12 hours. Water formed in the reaction mixture during this period is collected by a water separator. After cooling the benzene solution is washed with a 10% solution of sodium bicarbonate, water, saturated brine and dried over sodium sulfate.
- Example 2 may be used to prepare the products listed in Tables I and II.
- an equivalent amount of the starting material of formula II, listed therein is used instead of the starting material of formula II described in Example 2 and an equivalent amount of the corresponding ketoacid of formula VI of the ketoester of formula VI listed therein is used instead of the said ketoester.
- N,N-dicyclohexylcarbodiimide (17.36 g, 0.084 mole) is added to a cooled, stirred solution of the above primary alcohol (6.09 g, 0.028 mole) in 63 ml of dimethyl sulfoxidebenzene (2:1) containing trifluoroacetic acid (1.12 ml, 0.014 mole) and pyridine (2.24 ml, 0.028 mole).
- the reaction is stirred at room temperature under nitrogen for 5 hr.
- the reaction mixture is now diluted with 600 ml of ether, followed by the dropwise addition of a solution of oxalic acid (7.56 g) in 21 ml of methanol.
- Example 169 By following the procedure of Example 169 but using as starting material an equivalent amount of the appropriate starting material of formula II, for example, those described in Examples 1 to 168, inclusive, instead of tryptophol, and using an equivalent amount of the appropriate ketoalcohol lower alkyl ester of formula VIII, then the acid compounds of formula I in which R 7 is hydrogen and Z is hydroxy, for example, the respective products of Examples 1 to 168, inclusive, are obtained.
- Example 169 More specifically exemplified, according to the procedure of Example 169 the use of indole-3-ethanethiol and acetonyl acetate affords 1-methyl-1,3,4,9-tetrahydrothiopyrano[3,4-b]indole-1-acetic acid, identical to the product of Example 3. Similarly, the use of tryptophol and 5-acetoxypentan-2-one affords 1-methyl-1,3,4,9-tetrahydropyrano3,4-b]indole-1-propionic acid, identical to the product of Example 2.
- N-phenyl-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide, m.p. 205°-208° C, are obtained respectively.
- Example 304 By following the procedure of Example 304 but using as the starting material an equivalent amount of the ester compounds of formula I in which R 7 is hydrogen and Z is lower alkoxy, obtained prior to hydrolysis in Example 1 and 3 to 168, inclusive, instead of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid, and using an equivalent amount of an appropriate lower alkyl or lower alkenyl halide, then the corresponding N-alkylated ester compounds of formula I in which R 7 is lower alkyl or lower alkenyl, are obtained.
- Example 304 when following the procedure of Example 304, the replacement of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid by an equivalent amount of its corresponding ethyl ester, described in Example 1, and then use the same alkyl halide, methyl iodide, affords 1,9-dimethyl-1,3,4,9-tetrahydropyrano[3,4 -b]indole-1-acetic acid ethyl ester.
- Example 170 By following the procedure of Example 170 but using as the starting material an equivalent amount of one of the N-alkylated acid compounds of formula I, described in Examples 304 to 396, inclusive, instead of 1-methyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid, and using an equivalent amount of an appropriate amine such as ammonia or a primary or secondary amine, described in Example 170, then the corresponding amide compound of formula I in which R 7 is lower alkyl or lower alkenyl and Z is amino, lower alkyl amino, di(lower)alkylamino or phenylamino, is obtained. Examples of such amides are listed as products in Tables VII and VIII together with the appropriate starting material, noted by the example in which it is prepared, and the amine used for the preparation of the amide.
- the corresponding benzylamine salt is prepared by the mixing of equimolar ethereal solutions of benzylamine and the above product. The resulting solid is recrystallized from acetonitrile to afford 6-hydroxy-1-methyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid benzylamine salt, m.p. 191°-193° C.
- the corresponding acetate is prepared by allowing a mixture of the title compound and a five molar excess of acetic anhydride in pyridine solution to stand for 24 hr.
- Table IX provides further examples of the compounds of this invention.
- the remarks relating to procedure, starting material and product applied to Table I are applicable also to Table IX. Note also that starting materials of both formulae II and IIa are utilized.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Indole derivatives characterized by having a 1,3,4,9-tetrahydropyrano[3,4-b]indole or 1,3,4,9-tetrahydrothiopyrano[3,4-b]indole nucleus bearing a substituent in position 1, said substituent incorporating an acid, ester or amide function therein, are disclosed. The nucleus is further substituted at position 1 and may be optionally substituted at positions 3, 4, 5, 6, 7, 8, and 9. The derivatives are useful antiinflammatory, analgesic, antibacterial and antifungal agents and methods for their preparation and use are also disclosed.
Description
This is a division of application Ser. No. 555,506, filed Mar. 5, 1975, now U.S. Pat. No. 4,012,417, which Application is a continuation-in-part of our earlier-filed Application Ser. No. 513,693, filed October 10, 1974, now U.S. Pat. No. 3,974,179; which is a continuation-in-part of our earlier-filed Application Ser. No. 311,023, filed November 30, 1972, now abandoned, which is a continuation-in-part of our earlier-filed Application Ser. No. 289,714, filed September 15, 1972, now U.S. Pat. No. 3,939,178, which is a continuation-in-part of our earlier-filed Application Ser. No. 148,895, filed June 1, 1971 (now U.S. Pat. No. 3,843,681, issued October 22, 1974).
This invention relates to novel indole derivatives, to processes for their preparation and to intermediates used in these processes.
Notwithstanding the advances made during the last four decades in the development of agents for the treatment of inflammatory conditions, there still remains a need for effective agents without the side effects associated with the therapeutic agents presently used for this purpose.
The indole derivatives of this invention have been found to exhibit interesting and useful pharmacodynamic properties without eliciting undesirable side effects. Notable attributes of this effect are antiinflammatory and analgesic activities. In addition the compounds of this invention exhibit antibacterial and antifungal properties.
The indole derivatives of this invention are characterized by having a pyrano[3,4-b]indole or thiopyrano[ 3,4-b]indole nucleus bearing a substituent at positon 1, said substituent incorporating an acid, ester or amide function therein. These derivatives may be represented by formula I ##STR1## in which R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl and 2-thienyl, R2, R3, R4 and R5 are the same or different and are each selected from the group consisting of hydrogen and lower alkyl, R6 is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, phenyl, nitro, halo, mercapto, lower alkylthio, trifluoromethyl, amino and sulfamoyl, R7 is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, X is selected from the group consisting of oxy and thio, Y is selected from the group consisting of carbonyl, ##STR2## which each of R8, R9, R10, R11, R12 and R13 is hydrogen or lower alkyl, and Z is selected from the group consisting of hydroxy, lower alkoxy, amino, lower alkylamino, di(lower)alkylamino and phenylamino.
Also included within the scope of this invention are pyrano[3,4-b]indole and thiopyrano[3,4-b]indole derivatives of formula I in which R6 represents from one to four substituents, which may be present simultaneously, at positions 5,6,7 and 8 thereof. The exact nature of such substituents does not have to be limited necessarily by the above definitions of R6, and R6 may also include additional definitions, for example, mercapto, lower alkylthio, trifluoromethyl and other halo(lower)alkyls, amino and sulfamoyl, provided that any two such substituents do not interfere with each other. Accordingly, the indole derivatives of this invention are represented also be general formula Ia ##STR3## in which R1, R2, R3, R4, R5, R7, X, Y and Z are as defined in the first instance and R6a, R6b, R6c and R6d are the same or different and each is selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, phenyl, nitro, halo, mercapto, lower alkylthio, trifluoromethyl, amino and sulfamoyl.
The indole derivatives of this inventon of formula I are prepared by reacting a compound of the formula ##STR4## in which R2, R3, R4, R5, R6 and R7 are as defined in the first instance and X' is hydroxy or mercapto with a compound of formula ##STR5## in which R1, Y and Z are as defined in the first instance, in the presence of an acid catalyst.
The term "lower alkyl" as used herein contemplates both straight and branched chain alkyl radicals containing from one to six carbon atoms and includes methyl, ethyl, propyl, isopropyl, butyl, isobutyl, 2-methylpentyl and the like.
The term "lower alkenyl" as used herein contemplates both straight and branched chain alkenyl radicals containing from two to six carbon atoms and includes vinyl, allyl, 1-propenyl, methallyl, 2-ethyl-3-butenyl and the like.
The term "lower alkynyl" as used herein contemplates both straight and branched chain alkynyl radicals containing from two to six carbon atoms and includes ethynyl, propargyl, 1,1-dimethylpropargyl and the like.
The term " lower cycloalkyl" as used herein contemplates saturated cyclic hydrocarbon radicals containing from three to six carbon atoms and includes cyclopropyl, cyclobutyl, cyclopentyl and the like.
The term "lower alkoxy" as used herein contemplates both straight and branched chain alkoxy radicals containing from one to four carbon atoms and includes methoxy, ethoxy, isopropoxy and the like.
The term "lower alkanoyloxy" as used herein contemplates both straight and branched chain alkanoyloxy radicals containing from two to six carbon atoms and includes acetoxy, propionyloxy, hexanoyloxy and the like.
The term "halo" as used herein contemplates halogens and includes fluorine, chlorine, bromine and iodine.
Where the term "lower" is used herein as part of the description of alkylamino and dialkylamino, it contemplates one to six carbon atoms for each alkyl group of such a radical and includes methylamino, n-hexylamino, dimethylamino, diethylamino and the like.
The indole derivatives of formula I in which Z is hydroxy, the acid compounds of this invention, form addition salts with suitable inorganic and organic bases. These salts possess the same activities as the parent acid compound when administered to animals and may be utilized in the same manner. Suitable bases to form these salts include, for example, the hydroxides, lower alkoxides, carbonates and bicarbonates of sodium, potassium, calcium and magnesium, as well as the bases, ammonia, triethylamine, benzylamine and the like. The addition salts thus obtained are the functional equivalents of the parent acid compound in respect to their therapeutic use. Hence, these addition salts are included within the scope of this invention and are limited only by the requirement that the bases employed in forming the salts be pharmaceutically acceptable.
Also included within the scope of this invention are the isomers of the compounds of formula I resulting from the asymmetric centers contained therein.
The useful antiinflammatory and analgesic activities of the indole derivatives of this invention may be demonstrated in standard pharmacologic tests, for example, the tests described by R. A. Turner in "Screening Methods in Pharmacology", Academic Press, New York and London, 1965, pp. 152-163 and pp. 100-117, respectively,
More particularly, the antiinflammatory activity of the compounds of this invention may be readily demonstrated in a modification of the Freund's adjuvant test, the adjuvant induced acute edema test as described by J. R. Boissier, et al., Therapie, 25, 43 (1970). This test is known to correlate well with data derived from clinical results with humans. Boissier et al. have demonstrated this correlation with such clinically active compounds as phenylbutazone, mefenamic acid, indomethacin, aspirin, hydrocortisone and prednisolone.
More particularly exemplified, a substantial antiinflammatory effect for the compounds listed below is demonstrable at oral doses of 100 mg/kg or less in this acute edema test. In this test male rats are treated with the test compound one hour before the injection of Freund's adjuvant into the paw (day 0). The rats are then treated with the same dose of the test compound for the next three days. The antiinflammatory effect of the test compound is measured by the reduction of pedal inflammation, see Turner cited above, and expressed as a percent inhibition from adjuvant injected control rats on day 3.
______________________________________
PER-
DAILY CENT
DOSE INHI-
MG BI-
COMPOUND /KG) TION
______________________________________
1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]-
indole-1-acetic acid, Example No. 1
100 30
1-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]-
indole-1-acetic acid, Example No. 15
100 47
1-propyl-1,3,4,9-tetrahydropyrano[3,4-b]-
indole-1-acetic acid, Example No. 16
100 40
8-methyl-1-propyl-1,3,4,9-tetrahydropyrano-
[3,4-b]indole-1-acetic acid, Example No. 26
100 44
1-butyl-1,3,4,9-tetrahydropyrano[3,4-b]-
indole-1-acetic acid, Example No. 25
100 40
1-t-butyl-1,3,4,9-tetrahydropyrano[ 3,4-b]-
indole-1-acetic acid, Example No. 24
100 30
5-methyl-1-propyl-1,3,4,9-
tetrahydropyrano[3,4-b]-
indole-1-acetic acid, Example 32
100 44
1-ethyl-1,3,4,9-
tetrahydrothiopyrano[3,4-b]indole-
1-acetic acid, Example No. 98
25 32
______________________________________
The lack of side effects for the compounds of this invention may be demonstrated by standard acute toxicity tests (see Turner cited above) and by prolonged administration of the compound to warm-blooded animals.
When the present indole derivatives of this invention are employed as antiinflammatory and analgetic agents in warm-blooded animals, e.g., rats, they may be administered orally, alone or in dosage forms, i.e., capsules or tablets, combined with pharmacologically acceptable excipients, such as starch, milk sugar and so forth. They may also be administered orally in the form of solutions in suitable vehicles such as vegetable oils.
The dosage of the indole derivatives of this invention will vary with the particular compound chosen and form of administration. Furthermore, it will vary with the particular host under treatment. Generally, the compounds of this invention are administered at a concentration level that affords protective effects without any deleterious side effects. These antiinflammatorily-analgesically effective concentration levels are usually obtained within a therapeutic range of 1.0 mg to 500 mg/kg per day, with a preferred range of 10 to 100 mg/kg per day.
The indole derivatives of this invention also exhibit utility as antibacterial agents against a number of gram-positive and gram-negative microorganisms, such as, Staphylococcus pyrogenes, both penicillin sensitive and penicillin resistant, Streptococcus faecalis, Escherichia coli, Aerobacter aerogenes, Salmonella pullorum, Pseudomonas aerugenosa, Proteus mirabilis, Proteus vulgaris, Klebsiella pneumoniae and Serratia marcescens and as antifungal agents against a number of pathogenic fungi such as, Candida albicans, Microsporum gypseum and Trichophyton granulosum, in standard tests for antibacterial and antifungal activity, such as those described in "Antiseptics, Disinfectants, Fungicides and Sterilization", G. F. Reddish, Ed., 2nd ed., Lea and Febiger, Philadelphia, 1957 or by D. C. Grove and W. A. Randall in "Assay Methods of Antibiotics", Med. Encycl. Inc., New York 1955.
For example, by employing a test like the serial broth dilution test, see Grove and Randall, cited above, in which dilutions of the compounds of this invention in nutrient broth are inoculated with the microorganisms or fungi, described above, incubated at 37° C. for 2 days, respectively, and examined for the presence of growth, it may be shown that 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-propionic acid is able to inhibit growth totally in this system of Proteus vulgaris, Klebsiella pneumoniae and Serratia marcescens at a concentration of 100 mcg/ml. or less.
When the comounds of this invention are employed as antibiotic or antifungal agents in warm-blooded animals, e.g. rats, they may be administered alone or in combination with pharmacologically acceptable carriers. The proportion of the compound is determined by the solubility and chemical nature of the compound, chosen route of administration and standard biological practice. For example, they may be administered orally in solid form containing such excipients as starch, milk sugar, certain types of clay and so forth. They may also be administered orally in the form of solutions or they may be injected parenterally. For parenteral administration they may be used in the form of a sterile solution containing other solutes, for example, enough saline or glucose to make the solution isotonic.
The dosage of the present therapeutic agents as antibiotic or antifungal agents will vary with the form of administration and the particular compound chosen. Furthermore, it will vary with the particular host under treatment. Generally, treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached. In general, the compounds of this invention are most desirably administered at a concentration level that will generally afford antibacterially or antifungally effective results without causing any harmful or deleterious side effects and preferably at a level that is in a range of from about 1.0 mg. to about 1000 mg. per kilo per day, although as aforementioned variations will occur. However, a dosage level that is in the range of from about 10 mg. to about 500 mg. per kilo per day is most desirably employed in order to achieve effective results.
In addition, the agent may be employed topically. For topical application they may be formulated in the form of solutions, creams, or lotions in pharmaceutically acceptable vehicles containing 0.1-5 percent, preferably 2 percent, of the agent and may be administered topically to the infected area of the skin.
Also the antibacterial properties of the compounds of this invention may be utilized for washing equipment in hospitals, homes and farms, instruments used in medicine and bacteriology, clothing used in bacteriological laboratories, and floors, walls and ceiling in rooms in which a background free of gram-positive and gram-negative microorganisms, such as those listed above, is desired. When employed in this manner the compounds of this invention may be formulated in a number of compositions comprising the active compound and an inert material. In such compositions, while the compounds of formula I of this invention may be employed in concentrations as low as 500 p.p.m., from a practical point of view, it is desirable to use from about 0.10% by weight, to about 5% by weight or more.
The formulations that may be used to prepare antiseptic wash solutions of the compounds of this invention are varied and may readily be accomplished by standard techniques, see for example, "Remington's Practice of Pharmacy", E. W. Martin et al., Eds., 12th ed., Mack Publishing Company, Easton, Penn., 1961, pp. 1121 - 1150. In general, the compounds may be made up in stock solutions. They can also be formulated as suspensions in an aqueous vehicle. These make useful mixtures for decontaminating premises. Also, aqueous vehicles containing emulsifying agents, such as sodium lauryl sulfate, and relatively high concentrations, e.g., up to about 5% by weight, of the compounds may be formulated by conventional techniques.
A typical antiseptic preparation useful for disinfecting floors, walls, ceiling, and articles in a contaminated room may be prepared by adding 5 to 25 g. of N,N,1-trimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide to a mixture of 150 to 300 g. of polyethylene glycol 1540 and 150 to 300 g. of polyethylene glyol 300. The resulting mixture is stirred while a solution of 1 to 10 g. of sodium lauryl sulfate in 300 to 400 ml. of water is added portionwise. The article to be disinfected is coated or immersed in the preparation for a prolonged time, for example, one hour, and then rinsed with sterile water.
For the preparation of the indole derivatives of this invention we prefer to use as starting materials the compounds of the general formula II. ##STR6## in which R2, R3, R4, R5 , R6 and R7 are as defined in the first instance and X' is hydroxy or mercapto.
The starting materials of formula II in which X' is hydroxy are either known, for example, tryptophol, described by H. R. Snyder and F. J. Pilgrim, J. Am. Chem. Soc. 70, 3770 (1948), or they may be obtained by the following process: ##STR7##
With reference to this process phenylhydrazines of formula III and the hydroxyaldehyde of formula IV are reacted together according to the conditions of the "Fischer Indole Synthesis", for example, see P. L. Julian, E. N. Myer and H. C. Printy, "Heterocylic Compounds", R. C. Elderfield, Ed., Vol. 3, John Wiley and Sons, Inc., New York, 1952, pp. 8 - 11, to form the desired starting material (II, X' = OH).
The phenylhydrazines of formula III are either known or may be prepared according to known methods. A convenient method involves the diazotization of the appropriately substituted aniline to give the corresponding diazo derivative. The latter compound is then reduced with stannous chloride or sodium sulfite to give the corresponding phenylhydrazine, see L. F. Fieser and M. Fieser, "Advanced Organic Chemistry", Reinhold Publishing Corporation, New York, 1961, p. 734.
The hydroxyaldehydes of formula IV are either known, see for example, "Rodd's Chemistry of Carbon Compounds," S. Coffey, Ed., Vol. I d, 2nd ed., Elsevier Publising Co., Amsterdam, 1965, pp. 44 - 49, or they may be prepared according to known methods. A convenient method involves reduction of an appropriate lactone of formula ##STR8## with bis-(3-methyl-2-butyl)borane, H. C. Brown and D. B. Bigley J. Am. Chem. Soc., 83, 486 (1961), diisobutyl aluminum hydride, L. I. Zakharkkin and I. M. Khorlina, Tetrahedron Letters, 619 (1962) or sodium aluminum hydride, L. I. Zakharkin et al., Tetrahedron Letters, 2087 (1963). The appropriate lactones utilized in this reduction are either commercially available, for example, δ-valerolactone, α-methyl-butyrolactone, or they are described with a variety of methods for their preparation in organic chemistry textbooks; such as the textbooks, "Methoden der Organischen Chemie", Houben-Weyl, E. Muller, Ed., Vol. VI/2, Georg Thieme Verlag, Stuttgart, 1963, pp. 561- 852 or L. F. Fieser and M. Fieser, "Advanced Organic Chemistry", cited above.
Alternatively, the starting materials of formula II in which R2, R3, R4 and R7 are hydrogen and X' is hydroxy may be prepared by lithium aluminum hydride reduction, N. G. Gaylord, "Reduction with Complex Metal Hydrides", Interscience Publishers, Inc., New York, 1956, pp. 332 - 370, of compounds of formula V described by T.-Y. Shen, U.S. Pat. No. 3,161,654, Dec. 15, 1964: ##STR9## wherein R15 is lower alkyl and R5 and R6 are as defined in the first instance.
The starting materials of formula II in which X' is mercapto and R2, R3, R4, R5, R6, and R7 are as defined in the first instance may be obtained by the following process: The appropriate compound of formula II (X' = OH), described above, is treated with phosphorus tribromide in an inert solvent, for example, ether or carbon tetrachloride, to afford the corresponding 3-(2-bromoethyl)-indole derivative. The latter compound is then converted to the desired starting material of formula II (X' = SH) by a procedure similar to that described by N. N. Suvorov and V. N. Buyanov, Khim.-Farm. Zh., 1, 4 (1967), [Chem. Abstr. 67, 73474a (1967)], for converting 3-(2-bromoethyl)-indole to indole-3-ethanethiol (II; R2, R3, R4, R5, R6 and R7 = H and X' = SH). Accordingly, the appropriate 3-(2-bromoethyl)-indole derivative is treated with sodium or potassium thiosulfate to afford the corresponding sodium or potassium β-(3-indolyl)ethyl thiosulfate derivative, respectively, which on treatment with strong alkali for example, sodium or potassium hydroxide, is transformed into the corresponding bis-[ω-(3-indolyl)ethyl]disulfide derivative. Reduction of the latter compound with lithium aluminum hydride gives the desired compounds of formula II.
It should be noted that the preceding process is not entirely practical for the preparation of the compounds of formula II in which X' is mercapto and R6 is hydroxy or lower alkanoyloxy. For this reason, the preferred starting materials of formula II for the ultimate preparation of the compounds of formula I in which R6 is hydroxy or lower alkanoyloxy and X is thio are the corresponding compounds of formula II in which R6 is benzyloxy, readily prepared by this process. When the latter compounds are used as starting materials in this manner, they are first subjected to the process (II + VI→VII), described below. Subsequently, the benzyloxy group is removed by hydrogenation, in the presence of a catalyst, for example, 10% palladium on carbon, to afford the corresponding compound of formula I in which R6 is hydroxy. The latter may be converted if desired to the corresponding compound of formula I in which R6 is lower alkanoyloxy by conventional means, for example, by treatment with the appropriate lower alkanoic anhydride preferably in the presence of pyridine. Likewise, it should be noted that similar use of the starting materials of formula II in which X' is hydroxy and R6 is benzyloxy to obtain the corresponding compound of formula I in which R6 is hydroxy or lower alkanoyloxy is preferred.
For the preparation of the acid and ester compounds of this invention of formula I in which Z' is hydroxy or lower alkoxy and R1, R2, R3, R4, R5, R6, R7, X and Y are as defined in the first instance, we have found that the following, hitherto undisclosed process is both practical and convenient: ##STR10## in which R1, R2, R3, R4, R5, R6, R7, X, Y and Z are as defined in this instance, X' is hydroxy or mercapto and R16 is hydrogen or lower alkyl. (For convenience and clarity these particular acid and ester compounds of formula I are represented above as formula VII).
With reference to the above scheme the starting material of formula II is condensed with a ketoacid (VI, R16 = H) or a ketoester (VI, R16 = lower alkyl) in the presence of a suitable acid catalyst to yield the compounds of formula VII.
Generally comparable yields of product are obtained in this process when either the ketoacid or the corresponding ketoester is used. However, in the case where it is desired to prepare acid compounds of formula VII in which Y is ##STR11## and R16 is hydrogen, it is preferable with respect to yield to first condense the appropriate β-ketoester of formula VI rather than the corresponding β-ketoacid and then hydrolyze the resulting ester product to give the desired acid compound.
Moreover, in the general practice of this invention it is often more convenient to prepare the acid compounds of formula VII by using the ketoester instead of the ketoacid in this process and then hydrolyze the resulting ester product to the desired acid, the reason being simply that the ketoesters are generally more readily available either commercially or by synthesis.
The hydrolysis of compounds of formula VII in which R16 is lower alkyl to their corresponding acids of formula VII is readily effected by treatment with a suitable alkali, for example, potassium hydroxide or sodium carbonate, in aqueous methanol or aqueous ethanol.
In practising the condensation (II + VI→VII) we have found it preferable to use a solvent as a reaction medium. Any solvent inert to the reaction conditions may be used. Suitable solvents include benzene, toluene, diethyl ether, dioxan, tetrahydrofuran, methylene dichloride, carbon tetrachloride and the like. Benzene and tetrahydrofuran are especially convenient and practical for this use. A variety of suitable acid catalysts may be used for this condensation, for example, the type of catalyst used in a Friedel-Crafts Reaction, i.e. p-toluenesulfonic acid, phosphorus pentoxide, boron trifluoride, zinc chloride, hydrochloric acid and sulfuric acid and the like. p-Toluenesulfonic acid, boron trifluoride and phosphorus pentoxide are included among the preferred acid catalysts. The amount of acid catalyst used is not especially critical and may range from 0.01 molar equivalents to 100 molar equivalents; however, a range of from 0.1 to 10 molar equivalents is generally preferred. The time of the reaction may range from 10 minutes to 60 hours, with the preferred range being from one-half to 24 hours. The temperature of the reaction may range from -20° C. to the boiling point of the reaction mixture. Preferred temperature ranges include 20° to 120° C.
The α-, β-, γ- and δ- ketoacids and -ketoesters of formula VI are either known, for example, ethyl pyruvate, levulinic acid, ethyl α,α-dimethylacetoacetate, β,β-dimethyllevulic acid and benzoylacetic acid or they may be prepared by known methods described in general organic chemistry textbooks. For example, a comprehensive review on the properties and preparation of such α-, β-, γ- and δ- ketoacids and -ketoesters may be found in "Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1d, pp. 226 - 274.
Alternatively, the acid compounds of formula I in which Z is hydroxy and R1, R2, R3, R4, R5, R6, R7, X and Y are as defined in the first instance may be prepared by the following process: ##STR12## in which Y' is CH2, C(R8)(R9)CH2, C(R8) (R9)C(R10)(R11)CH2 or C(R8)R9)C(R10)(R11)C(R12)(R13)CH2, R17 is hydrogen or lower alkyl, Z is hydroxy and R1, R2, R3, R4, R5, R6, R7, X and Y are as defined in the first instance.
With reference to this alternative process a starting material of formula II is condensed with an acylated ketoalcohol (VIII) in the presence of a suitable acid catalyst according to the conditions described above for the condensation (II + VI→VII). The ketoalcohol lower alkyl esters are either known, for example, acetonyl acetate or 5-acetoxypentan-2-one, or may be prepared by known methods, for instance, see "Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1d, pp. 49 - 54. In this manner the condensation product of general formula IX is obtained. Hydrolysis of this product with an aqueous alcoholic solution of a suitable alkali, for example, sodium hydroxide in aqueous methanol, affords the corresponding primary alcohol X. The primary alcohol is then oxidized to the corresponding aldehyde of formula XI. Although a variety of methods are known for the oxidation of a primary alcohol to its corresponding aldehyde, see for example, "Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1c, pp. 4 - 10, we have found that the method of K. E. Pfitzner and J. G. Moffat, J. Am. Chem. Soc., 87, 5670 (1965) using N,N-dicyclohexylcarbodiimide and dimethyl sulfoxide in the presence of a suitable acid, for example, trifluoroacetic acid, to be both efficacious and convenient in this case. Subsequently the aldehyde XI may be converted to the desired acid compounds of formula I by a variety of oxidizing agents, including silver oxide, alkaline permanganate, hydrogen peroxide, peracids and the like. In this case we prefer to use silver oxide according to the method of M. Delepine and P. Bonnet, Compt. rend., 149,39 (1909).
The amide compound of this invention of formula I in which Z is amino, lower alkylamino, di(lower)alkylamino and phenylamino and R1, R2, R3, R4, R5, R6, R7, X and Y are as defined in the first instance, may be prepared from their corresponding acid compounds of formula I (compounds of formula VII in which R16 is hydrogen, described above) by treatment of the latter compounds with a lower alkyl chloroformate, preferably ethyl chloroformate, in the presence of triethylamine, affording the corresponding mixed anhydride, which is converted by treatment with the appropriate amine, such as ammonia, aniline or a suitable alkylamine or dialkylamine, to the desired amide compound of formula I.
Alternatively, these amides of formula I may be prepared from the corresponding esters of formula I (compounds of formulae VII, in which R16 is lower alkyl, described above) by treatment of the latter compounds with the appropriate amine according to known methods, for example, see A. L. J. Beckwith in "The Chemistry of Amides", J. Zalicky, Ed., Interscience Publishers, New York, 1970, pp. 96 - 105.
Again alternatively, the amide compounds of formula I in which Z is amino, lower alkylamino, di(lower)alkylamino, and phenylamino and R1, R2, R3, R4, R5, R6, R7, X and Y are as defined in the first instance, may be prepared by the condensation of an appropriate starting material of formula II with an appropriate α-, β-, γ- or δ-ketoamide in the presence of a suitable acid catalyst according to the conditions described above for the condensation (II + VI→VII). The ketoamides required for this condensation are either known, for example, pyruvamide or α,α-dimethylacetoacetamide, or they may be prepared by known methods, for instance, see "Rodd's Chemistry of the Carbon Compounds", cited above, Vol. 1d, pp. 226 - 274.
The alkylated acid and ester compounds of this invention of formula I in which R7 is lower alkyl or lower alkenyl and Z is hydroxy or lower alkoxy, are prepared readily from the above described, corresponding acid or ester compounds of formula I in which R7 is hydrogen. This conversion involving the N-alkylation of the indolic nitrogen is effected by treatment of the latter compounds with an appropriate lower alkyl or lower alkenyl halide in an inert solvent in the presence of an acid acceptor. Preferred conditions for effecting this conversion include the use of sodium hydride as an acid acceptor and tetrahydrofuran as the inert solvent.
The N-alkylated amide compounds of formula I in which R7 is lower alkyl or lower alkenyl and Z is amino, lower alkylamino, di(lower)alkylamino or phenylamino are preferably prepared by either treatment of the N-alkylated acid compounds of formula I, described above, with a lower alkyl chloroformate followed by treatment with the appropriate amine, or treatment of the N-alkylated ester compounds of formula I, described above, with an appropriate amine, in the manner described previously for the preparation of the amide compounds of formula I in which R7 is hydrogen.
Finally, it is the intention to cover all changes and modifications of the embodiment of the invention herein chosen for the purpose of disclosure which are within the scope and spirit of this invention. Such changes and modification include those variations which depend on well known interconversions of acids and esters or alternation of the order of N-alkylation in the processes disclosed herein.
For example, in preparing the N-alkylated acid, ester or amide compounds of formula I in which R7 is lower alkyl or lower alkenyl, the changing of the order of the N-alkylation step, as depicted in the embodiment of this invention, by the act of N-alkylation of the starting materials of formula II and subjecting the products thereof to treatment with an appropriate ketoacid or ketoester of formula VI or a ketoamide, according to the teaching of the present disclosure, would not depart from the spirit or scope of this invention.
Likewise, the preparation of the N-alkylated amide compounds of formula I in which R7 is lower alkyl or lower alkenyl and Z is di(lower)alkylamino by N-alkylation of the corresponding compounds of formula I in which R7 is hydrogen, is considered to be a process which would be functionally equivalent to the process embodied herein for the preparation of these compounds.
It will also be apparent to those skilled in the art that the processes taught herein for the preparation of the indole derivatives of formula I are applicable likewise to the preparation of the indole derivatives of formula Ia, described above. In the latter case, the appropriate starting material of formula IIa, see below, prepared analogously to the starting material of formula II, is utilized.
More specifically, the acid and ester compounds of formula Ia in which R6a, R6b, R6c, R6d and R7 are as defined in the first instance, Z is hydroxy or lower alkoxy, and R1, R2, R3, R4, R5, X and Y are as defined in the first instance, are readily prepared by the condensation (IIa+VI→VIIa), illustrated below, according to the conditions described previously for the condensation (II+VI→VII). ##STR13## in which R1, R2, R3, R4, R5, R6a, R6b, R6c, R6d, R7, X, Y and R16 are as defined in the first instance.
Likewise, the acid compounds of formula Ia in which R6a, R6b, R6c, R6d are as defined in the first instance, Z is hydroxy and R1, R2, R3, R4, R5, R7, X and Y are as defined in the first instance may be prepared by the following process: ##STR14## in which R1, R2, R3, R4, R5, X, Y, Y', R6a, R6b, R6c, R6d, R7, and R17 are as defined in the first instance according to the process disclosed above for the conversion {II+VIII→IX→X→XI→I (Z= OH)}. Subsquent transformation of the above acid and ester compounds of formula Ia to their corresponding N-alkylated and amide derivatives of formula Ia is effected in the same manner for the similar conversions of the acid ester compounds of formula I, described herein.
Alternatively, the amide derivatives of formula Ia are prepared by the condensation of an appropriate starting material of formula IIa with an appropriate α-, β-, γ- or δ-ketoamide in the presence of a suitable acid catalyst according to the conditions described previously for the condensation (II+VI→VII).
The following examples will illustrate further this invention.
Ethyl acetoacetate (23.4 g., 0.18 moles) is added to a solution of the starting material of formula II, tryptophol (10.0 g., 0.06 moles). in 200 ml. of benzene. After standing for 10 minutes, p-toluenesulfonic acid (1.3 g.) and about 5 g. of hydrated alkali-aluminum silicate (Molecular Sieves No. 4) are added. The mixture is subjected to reflux for thirty minutes, 600 mg. more of p-toluenesulfonic acid is added and refluxing continued for 21/2 hours. The molecular sieves are collected and the benzene solution washed successively with 5% sodium bicarbonate and water, dried over sodium sulfate, and evaporated under reduced pressure to dryness affording an oil. The oil is subjected to chromatography on silica gel. Elution with 5% ether in benzene yields the ester, 1-methyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid ethyl ester, as an oil, δmax CHCl.spsb.3 1715 cm-1.
Hydrolysis of this ester to the title compound is effected as follows: The ester is dissolved in 230 ml. of methanol. To this is added 10 g. of KOH in 30 ml. of H2 O and the solution is allowed to stand at room temperature overnight. The methanol is evaporated, water added and the solution washed with benzene. The aqueous phase is acidified with 6N HCl, and extracted with benzene. This organic phase is washed with water, dried over sodium sulfate and evaporated to dryness to give an oil, which is crystallized from benzene containing a trace of petroleum ether to afford the title compound, m.p. 150°- 152° C.,δmax CHCl.spsb.3 3325 and 1705 cm-1.
An equivalent amount of methyl acetoacetate may replace ethyl acetoacetate in the procedure of this Example. In this case, 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-acetic acid methyl ester, m.p. 87°-90° C. after recrystallization from benzenehexane, is obtained as the ester.
An equivalent amount of propyl acetoacetate may replace ethyl acetoacetate in the procedure of this Example. In this case, 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid propyl ester is obtained as the ester.
A mixture of the starting material of formula II, tryptophol (500 mg.) levulinic acid (580 mg.), 75 ml. of benzene, 1.7 g. of phosphorus pentoxide and about 0.5 g. of diatomaceous earth (Celite) is stirred magnetically at room temperature for 15 minutes and then at 70° C. for 11/2 hr. The reaction mixture is filtered. The filtrate is washed three times with 5N NaOH; the combined aqueous phase is washed twice with ether and then rendered acidic with cold 50% HCl. The aqueous phase is extracted with chloroform. The chloroform extract is dried (Na2 SO4) and evaporated to dryness. The residue is crystallized from ethyl acetate-petroleum ether to afford the title compound, m.p. 104°-110° C., nmr (CDCl3) δ1.47 (3H), 2.18 (4H), 2.74 (2H), 3.96 (2H), 7.18 (4H), 7.85 (1H), 9.60 (1.H).
The above title compound is also obtained by following the procedure of Example 1 but replacing ethyl acetoacetate with an equivalent amount of ethyl levulinate. In this case 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-propionic acid ethyl ester, m.p. 116°-118° C., δmax CHCl.spsb.3 1716 cm-1, after crystallization from benzene-petroleum ether, is obtained as the ester prior to hydrolysis.
Indole-3-ethanethiol (1.5 g.) and methyl acetoacetate are mixed with 50 ml. of benzene and the solution heated for 30 min. (bath temperature 70°-80° C.). p-Toluenesulfonic acid (0.15 g.) is added and the reaction mixture is subjected to reflux and stirring for 12 hours. Water formed in the reaction mixture during this period is collected by a water separator. After cooling the benzene solution is washed with a 10% solution of sodium bicarbonate, water, saturated brine and dried over sodium sulfate. Evaporation of the benzene solution yields the ester, 1-methyl-1,3,4,9-tetrahydrothiopyrano[3,4-b]indole-1-acetic acid methyl ester as a semi-solid, δmax CHCl.spsb.3 1715 cm-1.
This ester is then treated with aqueous alcoholic KOH in the manner described for the esters in Example 1 and 2 to afford the title compound, m.p. 147°-149° C., nmr (CDCl3) δ1.86 (S, 3H), 3.06 and 8.12 (6H), 7.35 (multiplet, 4H), 8.71 (1H), 10.31 (1H), after recrystallization from benzene-hexane.
The procedures of Examples 1, or 3 may be followed to prepare other compounds of formula I in which R1, R2, R3, R4, R5, R6, X and Y are as defined in the first instance, R7 is hydrogen and Z is hydroxy. Examples of such compounds of formula I are listed Tables I and II. In each of these examples an equivalent amount of the starting material of formula II listed therein is used instead of the starting material of formula II described in the procedures of Examples 1 and 3. Note that in each of these examples the ester obtained prior to hydrolysis is the corresponding ester compound of formula I in which Z is a lower alkoxy of the product listed therein, the alkyl portion of said lower alkoxy being derived from the R16 portion of the ketoester of formula VI employed therein.
Similarly, the procedure of Example 2 may be used to prepare the products listed in Tables I and II. In this case an equivalent amount of the starting material of formula II, listed therein is used instead of the starting material of formula II described in Example 2 and an equivalent amount of the corresponding ketoacid of formula VI of the ketoester of formula VI listed therein is used instead of the said ketoester.
TABLE I
KETOESTER OF PRODUCT:[(PREFIX FORMULA VI LISTED BELOW)-1,3,4,9
EX- FORMULA IISTARTING MATERIAL OF
##STR15##
(SUFFIX LISTED BELOW)][3,4-b]INDOLE-1-TETRAHYDROPYRANO
AMPLE R.sup.2 R.sup.4 R.sup.4 R.sup.6 R.sup.6 X R.sup.1 Y R.sup.16
PREFIX//SUFFIX
4 H H H H H O CH.sub.3 CO C.sub.2 H.sub.5 1-methyl//carboxylic
acid 5 CH.sub.3 H H H H O C.sub.2 H.sub.5 CO C.sub.2
H.sub.5 1-ethyl-3-methyl// carboxylic acid 6 n-C.sub.3
H.sub.7 H H H 5-CH.sub.3 O n-C.sub.3
H.sub.7 CO CH.sub.3 1,3-diisopropyl-6- methyl//carboxylic
acid 7 CH.sub.3 CH.sub.3 H H 5-OH O CH.sub.3 CHCH CO CH.sub.3
3,3-dimethyl-6-hydroxy 1-(1-propenyl)// carboxylic
acid 8 H H HH 7-C.sub.2 H.sub.5 O HCC CO CH.sub.3 8-ethyl-1-ethynyl//
carboxylic acid 9 H H 2-C.sub.3
H.sub.7 H H O
##STR16##
CO CH.sub.3 1-cyclopropyl-4-isopropyl//carboxylic acid 10 CH.sub.3
CH.sub.3 C.sub.2 H.sub.5C.sub.2
H.sub.5 H O
##STR17##
CO CH.sub.3 1-cyclopentyl-4,4-diethyl-3,3-dimethyl//carboxylic acid 11
H H H H H O
##STR18##
CO CH.sub.3 1-phenyl//carboxylicacid 12 CH.sub.3 C.sub.2 H.sub.5 H H H
O
##STR19##
CO CH.sub.3 1-benzyl-3-ethyl-3-methyl//carboxylicacid 13 H H H H 6-Cl O
##STR20##
CO 7-chloro-1-(2-thienyl)//carboxylicacid 14 HH CH.sub.3 H H O
CH.sub.3 CH.sub.2 CO C.sub. 2 H.sub.5 1,4-dimethyl//acetic
acid m.p. 163 - 164° C. 15 H H H H H O C.sub.2 H.sub.5 CH.sub.2
CO C.sub.2 H.sub.5 1-ethyl//acetic acid, m.p. 137 -
140° C. 16 H H H H H O n-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2
H.sub.5 1-propyl//acetic acid m.p. 148 - 151°
C. PRODUCT:[(PREFIX LISTED BELOW)-1,3,4,9- KETOESTER
OF TETRAHYDROPYRANO- EX- STARTING MATERIAL OF FORMULA VI [3,4-b]INDOLE-1-
AMPLE FORMULA II (R.sup.1COYOR.sup.16) (SUFFIX LISTED BELOW)] R.sup.2
R.sup.3 R.sup.4 R.sup.5 R.sup.6 X R.sup.1 Y R.sup.16 PREFIX//SUFFIX
17 H H H H H O i-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2
H.sub.5 1-isopropyl//acetic acid, m.p. 150 - 152° C.
18 CH.sub.3 H H H H O CH.sub.2CHCH.sub.2 CH.sub.2 CO C.sub.2 H.sub.5
1-allyl-3-methyl// acetic acid 19 CH.sub.3 H H H H O n-C.sub.3
H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 3-methyl-1-propyl// acetic
acid; m.p. 75 - 80° C. (Isomer A), m.p. 146 -
148° C (Isomer B). 20 CH.sub.3 H C.sub.2 H.sub.5
CH.sub.3 H O HCC CH.sub.2 CO C.sub.2 H.sub.5 4-ethyl-1-ethynl-3-
methyl//acetic acid, ν.sub.max.sup.CHCl 3 3300,2135,1710
c.sup.-m 21 H H H H H O CH.sub.3 CH(CH).sub.3 CO C.sub.2 H.sub.5
α,1-dimethyl//acetic acid; m.p. 154 - 156° C.
(Isomer A), m.p. 163 - 165°0 C. (Isomer B). 22 H
H H H H O
##STR21##
C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-cyclohexyl-α,α-dimethyl//acetic acid 23 H H H H H
O
##STR22##
CH.sub.2 CO C.sub.2 H.sub.5 1-phenyl//acetic acid,m.p. 148 -150°
C. 24 H H H H H O t-C.sub.4 H.sub.9 CH.sub.2 CO C.sub.2
H.sub.5 1-t-butyl//acetic acid, m.p. 210 - 212° C. 25
H H H H H O n-C.sub.4 H.sub.9 CH.sub.2 CO C.sub.2
H.sub.5 1-butyl//acetic acid m.p. 124 - 127° C. 26 H H
H H 7-CH.sub.3 O n-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2
H.sub. 5 8-methyl-1-propyl// acetic acid m.p.127 -
128 °
C. 27 H H H H H O
##STR23##
CH.sub.2 CO C.sub.2 H.sub.5 1-(2-thienyl)//aceticacid m.p. 127 -
130° C. 28 H H H H 5-Br O C.sub.2 H.sub.5 CH.sub.2 CO C.sub.2
H.sub.5 6-bromo-l-ethyl//acetic acid m.p. 182 - 184° C.
29 H H H H 5-OCH.sub.3 O CH.sub.3 CH.sub.2
CO CH.sub.3 6-methoxy-l-methyl// acetic acid, m.p.
142 - 143 ° C. 30 H H H H 5-OCOCH.sub.3 O CH.sub.3CH.sub.2 CO
C.sub.2 H.sub.5 6-acetoxy-l-methyl// acetic acid, m.p.
142 - 143° C. 31 H H H H 5-tenzyl- O CH.sub. 3 CH.sub.2 CO
C.sub.2 H.sub.5 6-benzyloxy-l-methyl/ oxy acetic acid, m.p.
163.5 ° C. 32 H H H H 4-CH.sub.3 O n-C.sub.3 H.sub.7
CH.sub.2 CO C.sub.2 H.sub.5 5-methyl-l-propyl// aceticacid,
m.p. 177 -178° C. 33 H H H H 6-CH.sub.3 O n-C.sub.3
H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 7-methyl-l-propyl// acetic
acid, m.p. 157 - 158° C. 34 H H H H 5-NO.sub.2 O
n-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 6-nitro-l-propyl//
acetic acid, m.p. 119 - 120° C. 35 i-C.sub.3 H.sub.7
H i-C.sub.3 H.sub.7 H 5-NO.sub.2 O CHCH CH(CH.sub.3 )00 C.sub.2 H.sub.5
3,4-diisopropyl-α- methyl-6-nitro-l- vinyl//ace
tic acid 36 H H CH.sub.3 CH.sub.3 H O n-C.sub.3 H.sub.7 CH.sub.2 CO
C.sub.2 H.sub.5 4,4-dimethyl-1- propyl//acetic acid, m.p. 184
- 185°C. 37 H H C.sub.2 H.sub.5 H 7-CH.sub.3 O HCC C(i-C.sub.3
H.sub.7).sub.2 CO C.sub.2 H.sub.5 α,α-diisopropyl-4-
ethyl-l-ethynyl-8- methyl//acetic acid 38 CH.sub.3 CH.sub.3
H H 5-OC.sub.2
H.sub.5 O
##STR24##
CH(C.sub.2 H.sub.7).sub.2 CO C.sub.2
H.sub.5 l-cyclopropyl-α,α-diethyl-3,5-dimethyl-6-ethoxy//ace
tic acid 39 CH.sub.3 CH.sub.3 C.sub.2 H.sub.5 C.sub.2 H.sub.5 6-O.sub.2
H.sub.5 O
##STR25##
C(CH.sub.3).sub.2 OO C.sub.2 H.sub.5 l-cyclohexyl-α,α t
,3,3,-etramethyl-4,4,7-triethyl//acetic acid 40 CH.sub.3 H n-C.sub.3
H.sub.7 n-C.sub.3 H.sub.7 4-N-C.sub.3
H.sub.7 O
##STR26##
CH(CH.sub.3)CO C.sub.2
H.sub.5 α,3-dimethyl-l-phenyl4,4,5-tripropyl//acetic acid 41 H H
H H H O
##STR27##
C(CH.sub.3).sub.2 CO C.sub.2 a
H.sub.5 α,α-dimethyl-1-phenyl//cetic acid 42 C.sub.2
H.sub.5 C.sub.2 H.sub.5 C.sub.2 H.sub.5 C.sub.2 H.sub.5 4-C.sub.2
H.sub.5 O
##STR28##
C(i-C.sub.3 H.sub.7).sub.2 CO C.sub.2
H.sub.5 1-benzyl-α,α-diisopropyl-3,3,4,4,5pentaethyl//acetica
cid 43 CH.sub.3 H H H
##STR29##
O
##STR30##
C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-benzyl-8-propionoxyα,α,3-trimethyl//acetic acid
44 H H CH.sub.3 H H O
##STR31##
CH(CH.sub.3)CO C.sub.2
H.sub.5 α,4-dimethyl-1-(2-thienyl)//aceticacid 45 H H H H H O
##STR32##
C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 α,α-dimethyl-1-(2-thienyl)//aceticacid 46 H H H H
4-I O i-C.sub.3 H.sub.7 CH.sub.2 CH.sub.2 CO C.sub.2
H.sub.5 5-iodo-1-isopropyl// propionic acid 47 CH.sub.3
CH.sub.3 CH.sub.3 CH.sub.3
##STR33##
O CH.sub.2CH CH.sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 8-acetoxy-α,3,3,4,4-pentamethyl-1-vinyl//propionic acid
48 H H H H 6-OH O HCCCH.sub.2 C(C.sub.2 H.sub.5).sub.2 CH.sub.2 CO
C.sub.2
H.sub.5 β,β-diethyl-7-hydroxy- 1-(2-propynyl)//
propionic acid 49 CH.sub.3 H H H 7-NO.sub.2 O
##STR34##
CH.sub.2 CH(n-C.sub.3 H.sub.7)CO C.sub.2
H.sub.5 1-cyclobutyl-3-methyl-8-nitro-α-propyl//propionic acid 50
H H CH.sub.3 H 5-CH.sub.3 O
##STR35##
C(CH.sub.3).sub.2 C(CH.sub.3 ).sub.2 CO C.sub.2
H.sub.5 α,α,β,β,4,6-hexamethyl1-phenyl//propionica
cid 51 i-C.sub.3
H.sub.7 H H H 7-Br O
##STR36##
CH(CH.sub.3)CH(C.sub.2 H.sub.5)CO C.sub.2
H.sub.5 1-benzyl-8-bromo-α-ethyl-3-isopropyl-β-methyl//propio
nicacid 52 C.sub.2 H.sub.5 H C.sub.2
H.sub.5 H 7-Cl O
##STR37##
CH.sub.2 CH.sub.2 CH.sub.2 CO C.sub.2
H.sub.5 8-chloro-3,4-diethyl-1-(2-thienyl)//propionic acid 53 CH.sub.3
H H H H O CH.sub.3 CH.sub.2 C(n-C.sub.3 H.sub.7).sub.2 CO C.sub.2
H.sub.5 1,3-dimethyl-α,α- dipropyl//propionic
acid 54 CH.sub.3 H C.sub.2 H.sub.5 C.sub.2
H.sub.5 H O
##STR38##
CH(CH.sub.3)C(CH.sub.3).sub.2
CO CH.sub.3
##STR39##
55 H H CH.sub.3 CH.sub.3 H O HCC C(CH.sub.3).sub.2 CH.sub.2 CO CH.sub.3
1-ethynyl-β,β,4,4- tetramethyl//propionic
acid 56 H H n-C.sub.3
H.sub.7 H
##STR40##
O
##STR41##
C(C.sub.2 H.sub.5).sub.2 C(C.sub.2
H.sub.5)CO CH.sub.3 1-cyclopentyl-5-propionoxy-4-propyl-α,β,.
beta.-triethyl//propionic acid 57 n-C.sub.3 H.sub.7 H H H 4-OCH.sub.3 O
##STR42##
CH.sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 5-methoxy-α-methyl-1-phenyl-3-propyl//propionic acid 58 H
H i-C.sub.3
H.sub.7 H 6-benzyloxy O
##STR43##
CH.sub.2 CH(C.sub.2 H.sub.5)CO C.sub.2
H.sub.5 1-benzyl-7-benzyloxy-α-ethyl-4-isopropyl//propionic acid
59 CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3 7-Cl O
##STR44##
CH(CH.sub.3)CH.sub.2 CO C.sub.2
H.sub.5
##STR45##
60 C.sub.2 H.sub.5 H H H 5-NO.sub.2 O CH.sub.3 CH(C.sub.2
H.sub.5).sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5 1-methyl-6-nitro-α,α,- β,β,3-pen
taethyl// propionic acid 61 C.sub.2 H.sub.5 C.sub.2 H.sub.5 H
H 5-F O CH.sub.2CHCH.sub.2 CH(C.sub.2 H.sub.5)CH(CH.sub.3)CO C.sub.2
H.sub.5 1-allyl-6-fluoro-α- methyl-β,3,3-triethyl//
propionic acid 62 C.sub.2 H.sub.5 C.sub.2
H.sub.5 H H 4-C.sub.2 H.sub.5 O CH.sub.3 CCH C(n-C.sub.3
H.sub.7)CH.sub.2
CO CH.sub.3 β propyl-1-(1-
propynyl)-3,3,5- triethyl//propionic acid 63 H
H H H 6-OC.sub.2
H.sub.5 O
##STR46##
CH(C.sub.2 H.sub.5)CH(C.sub.2 H.sub.5)CO C.sub.2
H.sub.5 1-cyclopropyl-α,β-diethyl-6-ethoxy//propionic acid
64 CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3 6-On-C.sub.3
H.sub.7 O
##STR47##
C(CH.sub.3).sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 α,β,β,3,3,4,4-heptamethyl-1-phenyl-7-propoxy//pr
opionicacid 65 C.sub.2 H.sub.5 C.sub.2
H.sub.5 H H 5-CH.sub.3 O
##STR48##
C(CH.sub.3).sub.2 C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-benzyl-3,3-diethyl-α,α,β,β,6-pentamethyl
//propionic acid 66 n-C.sub.3
H.sub.7 H H H 4-OH O
##STR49##
C(CH.sub.3).sub.2 C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 5-hydroxy-3-propyl-α,α,β,β-tetramethyl-1-(
2-thienyl)//propionic acid 67 H H H H H O CH.sub.3 CH.sub.2 CH.sub.2
CH.sub.2 CO C.sub.2 H.sub.5 1-methyl//butyric acid, m.p. 132 -
135° C 68 CH.sub.3 H H H H O C.sub.2 H.sub.5 CH(CH.sub.3)CH.sub.2
CH.sub.2 CO C.sub.2 H.sub.5 γ,3-dimethyl-1-ethyl//
butyric acid 69 CH.sub.3 CH.sub.3 H H H O n-C.sub.3 H.sub.7 C(C.sub.2
H.sub.5).sub.2 CH.sub.2 CH.sub.2 CO C.sub.2
H.sub.5 γ,γ-diethyl-3,3- dimethyl-1-propyl//
butyric acid 70 CH.sub.3 CH.sub.3 n-C.sub.3
H.sub.7 H H O CH.sub.2CH C(n-C.sub.3 H.sub.7).sub.2 CH(n-C.sub.3
H.sub.7)CH.sub.2 CO C.sub.2
H.sub.5 3,3-dimethyl-β,γ,γ,4- tetrapropyl-1-v
inyl// butyric acid 71 H H H H H O CH.sub.2CHCH.sub.2 [C(CH.sub
.3).sub.2 ].sub.2 CH.sub.2 CO C.sub.2
H.sub.5 1-allyl-β,β,γ,γ- tetramethyl//bu
tyric acid 72 H H C.sub.2 H.sub.5 C.sub.2 H.sub.5 6-Cl O
CH.sub.2CH [C(C.sub.2 H.sub.5).sub.2 ].sub.2 CH(C.sub.2 H.sub.5)CO
C.sub.2 H.sub.5 7-chloro-α,β,β,γ,γ,4,-
4-heptaethyl-1-vinyl// butryic acid 73 H H CH.sub.3 H
4-CH.sub.3 O HCCH [C(CH.sub.3).sub.2 ].sub.3 CO C.sub.2
H.sub.5 1-ethynyl-α,α,β,β,γ,γ,
4,5-octamethyl// butyric acid 74 C.sub.2 H.sub.5 C.sub.2
H.sub.5 C.sub.2
H.sub.5 H
##STR50##
O CH.sub.3 CCH CH(C.sub.2 H.sub.5)[C(C.sub.2 H.sub.5)].sub.2 CO C.sub.2
H.sub.5
##STR51##
75 H H CH.sub.3 CH.sub.3 7-OCH.sub.3 O
##STR52##
CH.sub.2 [C(CH.sub. 3).sub.2 ].sub.2 CO C.sub.2
H.sub.5 1-cyclobutyl-α,α,β,β,-4,4-hexamethyl-8-met
hoxy//butyric acid 76 H H H H 4-Br O
##STR53##
CH.sub.2 CH(CH.sub.3)C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 5-bromo-1-cyclopentyl-α,α,β-trimethyl//butyric
acid 77 CH.sub.3 CH.sub.3 H H 4-n-C.sub.3
H.sub.7 O
##STR54##
CH.sub.2 CH.sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5
##STR55##
78 H H H H 7-C.sub.2
H.sub.5 O
##STR56##
CH.sub.2 CH.sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5
##STR57##
79 CH.sub.3 CH.sub.3 CH.sub.3 H 5-F O
##STR58##
[CH(CH.sub.3)].sub.3 CO C.sub.2
H.sub.5
##STR59##
80 CH.sub.3 CH.sub.3 H H 4-CH.sub.3 O
##STR60##
CH(C.sub.2 H.sub.5)CH.sub.2 CH(C.sub.2 H.sub.5)CO C.sub.2 H.sub.5
##STR61##
81 C.sub.2
H.sub.5 H H H 6-NO.sub.2 O
##STR62##
[CH(CH.sub.3)].sub.3 CO C.sub.2
H.sub.5 1-benzyl-3-ethyl-7-nitro-α,β,γ-trimethyl//butyr
icacid 82 CH.sub.3 CH.sub.3 H H 4-n-C.sub.3
H.sub.7 O
##STR63##
CH.sub.2 [CH(C.sub.2 H.sub.5)].sub.2 CO C.sub.2
H.sub.5 1-benzyl-α,β-diethyl-3,3-dimethyl-5-propyl//butyric
acid 83 H H H H 7-OH O
##STR64##
C(CH.sub.3).sub.2 CH.sub.2 C(CH.sub.3).sub.2 CO C.sub.2 H.sub.5
1-benzyl-8-hydroxy-α,α,γ,γ-tetramethyl//butyric
acid 84 CH.sub.3 H CH.sub.3 H 4-OC.sub.2
H.sub.5 O
##STR65##
[C(CH.sub.3).sub.2 ].sub.3 CO C.sub.2
H.sub.5 5-ethoxy-α,α,β,β,γ,γ,-3,4-octo
methyl-1-(2-thienyl)//butyric acid 85 C.sub.2 H.sub.5 H C.sub.2 H.sub.5
C.sub.2 H.sub.5 6-Cl O
##STR66##
CH.sub.2 CH.sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5 7-chloro-α,α,3,4,4-pentaethyl-1-(2-thienyl)//butyric
acid 86 CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3 4-Br O
##STR67##
CH.sub.2 CH.sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 5-bromo-α,3,3,4,4-pentamethyl-1-(2-thienyl)//butyric
acid
TABLE 2
KETOESTER OF PRODUCT: [(PREFIX FORMULA VI LISTED BELOW)-1,3,4,9-
EX- FORMULA IISTARTING MATERIAL OF
##STR68##
(SUFFIX LISTED BELOW)[3,4-b]INDOLE-1- AMPLE R.sup.2 R.sup.3 R.sup.4
R.sup.5 R.sup.6 X R.sup.1 Y R.sup.16 PREFIX//SUFFIX
87 H H H H S CH.sub.3 CO C.sub.2 H.sub.5 1-methyl//carboxylic
acid 88 CH.sub.3 H H H H S C.sub.2 H.sub.5 CO C.sub.2
H.sub.51-ethyl-3-methyl// carboxylic acid 89 i-C.sub.3
H.sub.7 H H H 5-CH.sub.3 S i-C.sub.3
H.sub.7 CO CH.sub.3 1,3-diisopropyl-6- methyl//carboxylic
acid 90 CH.sub.3 CH.sub.3 H H 5-OH S CH.sub.3 CHCHCO CH.sub.3
3,3-dimethyl-6- hydroxy-1-81-propenyl)// carboxylic
acid 91 H H H H 7-C.sub.2 H.sub.5 S HCC CO CH.sub.3 8-ethyl-1-ethynyl//
carboxylic acid 92 H H i-C.sub.3
H.sub.7 H H S
##STR69##
CO CH.sub.3 1-cyclopropyl-4-iso-propyl//carboxylicacid 93 CH.sub.3
CH.sub.3 C.sub.2 H.sub.5 C.sub.2
H.sub.5 H S
##STR70##
CO CH.sub.3 1-cyclopentyl-4,4-diethyl-3,3-dimethyl//carboxylic acid 94
H H H H H S
##STR71##
CO CH.sub.3 1-phenyl//carboxylicacid 95 CH.sub.3 C.sub.2 H.sub.5 H H H
S
##STR72##
CO CH.sub.3 1-benzyl-3-ethyl-3-methyl//carboxylicacid 96 H H H H 6-Cl S
##STR73##
CO 7-chloro-1-(2-thienyl)//carboxylic acid 97 H H CH.sub.3 H H S
CH.sub. 3 CH.sub.2 CO C.sub.2 H.sub.5 1,4-dimethyl//acetic
acid 98 H H H H H S C.sub.2 H.sub.5 CH.sub.2 CO C.sub.2
H.sub.5 1-ethyl//acetic acid, m.p. 138° C. 99 H H H H
H S n-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 1-propyl//acetic acid,
m.p. 127-129° C. 100 H H H H H S i-C.sub.3 H.sub.7
CH.sub.2 CO C.sub.2 H.sub.5 1-isopropyl//acetic acid 101
CH.sub.3 H H H H S CH.sub.2 =CHCH.sub.2 CH.sub.2 CO C.sub.2 H.sub.5
1-allyl-3-methyl// acetic acid 102 CH.sub.3 H H H H S n-C.sub.3
H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 3-methyl-1-propyl//
acetic acid 103 CH.sub.3 H C.sub.2 H.sub.5 CH.sub.3 H S HC C CH.sub.2 CO
C.sub.2 H.sub.5 4-ethyl-1-ethynyl- 3-methyl//acetic
acid 104 H H H H H S CH.sub.3 CH(CH.sub.3)CO C.sub.2
H.sub.5 α,1-dimethyl//acetic acid 105 H H H H H S
##STR74##
C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-cyclohexyl-α,α-dimethyl//aceticacid 106 H H H H H
S
##STR75##
CH.sub.2 CO C.sub.2 H.sub.5 1-phenyl//aceticacid 107 H H H H H S
t-C.sub.4 H.sub.9 CH.sub.2 CO C.sub.2 H.sub.5 1-t-butyl//acetic
acid 108 H H H H H S n-C.sub.4 H.sub.9 CH.sub.2 CO C.sub.2 H.sub.5
1-butyl//acetic acid 109 H H H H 7-CH.sub.3 S n-C.sub.3 H.sub.7 CH.sub.2
CO C.sub.2 H.sub.5 8-methyl-1-propyl// acetic acid 110 H H H H
H S
##STR76##
CH.sub.2 CO C.sub.2 H.sub.5 1-(2-thienyl)//acetic acid 111 H H H H 5-Br
S n-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 6-bromo-1-propyl//
acetic acid 112 H H H H 5-och.sub.3 S CH.sub.3 CH.sub.2 CO CH.sub.3
6-methoxy-1-methyl// acetic acid 113 H H H H 5-COOCH.sub.3 S
CH.sub.3 CH.sub.2 CO C.sub.2 H.sub.5 6-acetoxy-1-methyl// acetic acid
114 H H H H 5-benzyl- S CH.sub.3 CH.sub.2 CO C.sub.2
H.sub.5 6-benzyloxy-1- oxy methyl//acetic acid 115 H H H H 4-CH.sub.3
S n-C.sub.3 H.sub.7 CH.sub.2 CO C.sub.2 H.sub.5 5-methyl-1-propyl//
acetic acid 116 H H H H 6-CH.sub.3 S n-C.sub.3 H.sub.7 CH.sub.2 CO
C.sub.2 H.sub.5 7-methyl-1-propyl// acetic acid 117 H H H H 7-F S
CH.sub.2CH C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5 α,α-diethyl-8- fluoro-1-vinyl// acetic acid 118
i-C.sub.3 H.sub.7 H i-C.sub.3
H.sub.7 H 5-NO.sub.2S CH.sub.2CH CH)CH.sub.3)CO C.sub.2 H.sub.5
3,4-diisopropyl-α- methyl-6-nitro- 1-vinyl//acetic acid 119
CH.sub.3 CH.sub.3 H H 5-Cl S CH.sub.3 CC CH(i-C.sub.3 H.sub.7)CO C.sub.2
H.sub.5 6-chloro-3,3-dimethyl α
isopropyl-1- (1-propynyl)//acetic acid 120 H H C.sub.2 H.sub.5 H
7-CH.sub.3 S HCC C(i-C.sub.3 H.sub.7).sub.2 CO C.sub.2
H.sub.5 α,α-diisopropyl- 4-ethyl-1-ethynyl- 8-methyl//acet
ic acid 121 CH.sub.3 CH.sub.3 H H 5-OC.sub.2
H.sub.5 S
##STR77##
CH(C.sub.2 H.sub.5)CO C.sub.2
H.sub.5 1-cyclopropyl-α,α-diethyl-3,3-dimethyl-6-ethoxy//ace
tic acid 122 CH.sub.3 CH.sub.3 C.sub.2 H.sub.5 C.sub.2 H.sub.5 6-C.sub.2
H.sub.5 S
##STR78##
C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-cyclohexyl-α,α,3,3-tetramethyl-4,4,7-triethyl//ace
ticacid 123 CH.sub.3 H n-C.sub.3 H.sub.7 n-C.sub. 3 H.sub.7 4-n-C.sub.3
H.sub.7 S
##STR79##
CH(CH.sub.3)CO C.sub.2
H.sub.5 α,3-dimethyl-1-phenyl-4,4,5-tripropyl//acetic acid 124 H
H H H H S
##STR80##
C(CH.sub.3).sub.2 CO C.sub.2 a
H.sub.5 α,α-dimethyl-1-phenyl//cetic acid 125 C.sub.2
H.sub.5 C.sub.2 H.sub.5 C.sub.2 H.sub.5 C.sub.2 H.sub.5 4-C.sub.2
H.sub.5 S
##STR81##
C(i-C.sub.3 H.sub.7).sub.2 CO C.sub.2
H.sub.5 1-benzyl-α,α-diisopropyl-3,3,4,4,5-pentaethyl//aceti
cacid 126 CH.sub.3 H H H
##STR82##
S
##STR83##
C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-benzyl-8-propionoxy-α,α,3-trimethyl//acetic acid
127 H H CH.sub.3 H H S
##STR84##
CH(CH.sub.3)CO C.sub.2
H.sub.5 α,4-dimethyl-1-(2-thienyl)//aceticacid 128 H H H H H S
##STR85##
C(CH.sub.3).sub.2 CO C.sub. 2
H.sub.5 α,α-dimethyl-1-(2-thienyl)//aceticacid 129 H H H H
H S CH.sub.3 CH.sub.2 CH.sub.2 CO C.sub.2 H.sub.5 1-methyl// propionic
acid 130 CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3
##STR86##
S CH.sub.2CH CH.sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 8-acetoxy-α,3,3,4,4-pentamethyl-1-vinyl//propionic 131 H
H H H 6-OH S HCCCH.sub.2 CH.sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5 β,β-diethyl-7-hydroxy- 1-(2-propionyl)// propionic
acid 132 CH.sub.3 H HH 7-NO.sub.2 S
##STR87##
CH(n-C.sub.3 H.sub.7)CH.sub.2 CO C.sub.2 H.sub.5 1-cyclobutyl-3-methyl-
8-nitro-α-propyl// propionic acid 133 H H CH.sub.3 H 5-CH.sub.3
S
##STR88##
C(CH.sub.3).sub.2 C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 α,α,β,β4,6-hexamethyl-1-phenyl//propionica
cid 134 i-C.sub.3
H.sub.7 H H H 7-Br S
##STR89##
CH(CH.sub.3)CH(C.sub.2 H.sub.5 )CO C.sub.2
H.sub.5 1-benzyl-8-bromo-αethyl-3-isopropyl-βmethyl//propioni
cacid 135 C.sub.2 H.sub.5 H C.sub.2
H.sub.5 H 7-Cl S
##STR90##
CH.sub.2 CH.sub.2 CH.sub.2 CO C.sub.2
H.sub.5 8-chloro-3,4-diethyl-1-(2-thienyl)//propionic acid 136 CH.sub.3
H H H H S CH.sub.3 CH.sub.2 C(n-C.sub.3 H.sub.7).sub.2 CO C.sub.2
H.sub.5 1,3-dimethyl-α,α- dipropyl//propionic acid 137
CH.sub.3 H C.sub.2 H.sub.5 C.sub.2
H.sub.5 H S CH.sub.2C(CH.sub.3)CH.sub.2 CH(CH.sub.3)C(CH.sub.3).sub.2
CO CH.sub.3 4,4-diethyl-1- methalkyl-α,α,β,3-
tetamethyl// propionic acid 138 H H CH.sub.3 CH.sub.3 H S HCC C(CH.sub.3
).sub.2 CH.sub.2
CO CH.sub.3 1-ethynyl-β,β,4,4- tetramethyl//propionic acid
139 H H n-C.sub.3
H.sub.7 H
##STR91##
S
##STR92##
C(C.sub.2 H.sub.5).sub.2 C(C.sub.2
H.sub.5)CO CH.sub.3 1-cyclopentyl-5-propionoxy-4-propyl- α,β,
β-triethyl//propionic acid 140 n-C.sub.3 H.sub.7 H H H 4-OCH.sub.3
S
##STR93##
CH.sub.2 CH(CH.sub.3 (COC.sub.2
H.sub.5 5-methoxy-α-methyl-1-phenyl-3-propyl//propionic acid 141
H H i-C.sub.3
H.sub.7 H 6-benzyl-oxy S
##STR94##
CH.sub.2 CH(C.sub.2 H.sub.5)CO C.sub.2
H.sub.5 1-benzyl-6-benzyloxy-α-ethyl-4-isopropyl//propionic acid
142 CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3 7-Cl S
##STR95##
CH(CH.sub.3)CH.sub.2 CO C.sub.2
H.sub.5 8-chloro-β,3,3,4,4-pentamethyl-1-(2-thienyl)//propionicacid
143 C.sub.2 H.sub.5 H H H 5-NO.sub.2 S CH.sub.3 CH(C.sub.2
H.sub.5).sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5 1-methyl-6-nitro-α,α, β,β,3-pentaethyl//
propionic acid 144 C.sub.2 H.sub.5 C.sub.2
H.sub.5 H H 5-F S CH.sub.2CHCH.sub.2 CH(C.sub.2 H.sub.5)CH(CH.sub.3)CO
C.sub.2 H.sub.5 1-allyl-6-fluoro-α- methyl-β,3,3-triethyl//
propionic acid 145 C.sub.2 H.sub.5 C.sub.2 H.sub.5 H H 4-C.sub. 2
H.sub.5 S CH.sub.3 CHCH C(n-C.sub.3 H.sub.7)CH.sub.2 CO CH.sub.3
β propyl-1-(1- propynyl)-3,3,5- triethyl//propionic acid 146 H
H H H 6-OC.sub.2
H.sub.5 S
##STR96##
CH(C.sub.2 H.sub.5)CH(C.sub.2 H.sub.5)CO C.sub.2
H.sub.5
##STR97##
147 CH.sub.3 CH.sub.3 CH.sub.3 CH.sub.3 6-O-n-C.sub.3 H.sub.7 S
##STR98##
C(CH.sub.3).sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 α,β,β,3,3,4,4-heptamethyl-1-phenyl-7-propoxy//pr
opionicacid 148 C.sub.2 H.sub.5 C.sub.2 H.sub.5 H H 5-CH.sub.3 S
##STR99##
C(CH.sub.3).sub.2 C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 1-benzyl-3,3-diethyl-α,α,β,β,6-pentamethyl
//propionic acid 149 n-C.sub.3
H.sub.7 H H H 4-OH S
##STR100##
C(CH.sub.3).sub.2 C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5
##STR101##
150 H H H H H S CH.sub.3 CH.sub.2 CH.sub.2 CH.sub.2 CO C.sub.2 H.sub.5
1-methyl//butyric acid 151 CH.sub.3 H H H H S C.sub.2
H.sub.5 CH(C.sub.2 H.sub.5).sub.2 CH.sub.2 CH.sub.2 CO C.sub.2 H.sub.5
γ,3-dimethyl-1-ethyl// butyric acid 152 CH.sub.3 CH.sub.3 H H H S
n-C.sub.3 H.sub.7 C(C.sub.2 H.sub.5).sub.2 CH.sub.2 CH.sub.2 CO C.sub.2
H.sub.5 γ,γ-diethyl-3,3- dimethyl-1-propyl// butyric acid
153 CH.sub.3 CH.sub.3 n-C.sub.3 H.sub.7 H H S CH.sub.2CH C(n-C.sub.3
H.sub.7).sub.2 CH(n-C.sub.3 H.sub.7)CH.sub.2 CO C.sub.2
H.sub.5 3,3-dimethyl-β,γ,γ,4- tetrapropyl-1-vinyl//
butyric acid 154 H H H H H S CH.sub.2CHCH.sub.2 [C(CH.sub.3).sub.2
].sub.2 CH.sub.2 CO C.sub.2
H.sub.5 1-allyl-β,β,γ,γ- tetramethyl//butyric
acid 155 H H C.sub.2 H.sub.5 C.sub.2
H.sub.5 6-Cl S CH.sub.2CH [C(C.sub.2 H.sub.5).sub.2 ].sub.2 CH(C.sub.2
H.sub.5)CO C.sub.2
H.sub.5 7-chloro-α ,β,β,γ,γ,4- 4-heptaethyl
-1-vinyl// butyric acid 156 H H CH.sub.3 H 4-CH.sub.3 S HCCH [C(CH.sub.3
).sub.2 ].sub.3 CO C.sub.2
H.sub.5 1-ethynyl-α,α,β,β,γ,γ-,
4,5-octamethyl// butyric acid 157 C.sub.2 H.sub.5 C.sub.2 H.sub.5
C.sub.2
H.sub.5 H
##STR102##
S CH.sub.3 CCH CH(C.sub.2 H.sub.5)[C(C.sub.2 H.sub.5)].sub.2 CO C.sub.2
H.sub.5 6-acetoxy-α,α,β,β,γ,3-, 3,4-octaethy
l-1- (1-propynyl)//butyric acid 158 H H CH.sub.3 CH.sub.3 7-OCH.sub.3
S
##STR103##
CH.sub.2 [C(CH.sub.3).sub.3 ].sub.2 CO C.sub.2
H.sub.5 1-cyclobutyl-α,α,β,β,- 4,4-hexamethyl-8-
methoxy//butyric acid 159 H H H H 4-Br S
##STR104##
CH.sub.2 CH(CH.sub.3)C(CH.sub.3).sub.2 CO C.sub.2
H.sub.5 5-bromo-1-cyclopentyl-α,α,β-trimethyl//butyric
acid 160 CH.sub.3 CH.sub.3 H H 4-n-C.sub.3
H.sub.7 S
##STR105##
CH.sub.2 CH.sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5 1-cyclopropyl-α,α-diethyl-3,3-dimethyl-5-propyl//but
yricacid 161 H H H H 7-C.sub.2
H.sub.5 S
##STR106##
CH.sub.2 CH.sub.2 CH(CH.sub.3)CO C.sub.2
H.sub.5 8-ethyl-α-methyl-1-phenyl//butyric acid 162 CH.sub.3
CH.sub.3 CH.sub.3 H 5-F S
##STR107##
[CH(CH.sub.3)].sub.3 CO C.sub.2
H.sub.5 6-fluoro-α,β,γ,3,3,4-hexamethyl-1-phenyl//butyr
ic acid 163 CH.sub.3 CH.sub.3 H H 4-CH.sub.3 S
##STR108##
CH(C.sub.2 H.sub.5)CH.sub.2 CH(C.sub.2 H.sub.5)CO C.sub.2 H.sub.5
α,γ-diethyl-1-phenyl-3,3,5-trimethyl//butyric acid 164
C.sub.2
H.sub.5 H H H 6-NO.sub.2 S
##STR109##
[CH(CH.sub.3)].sub.3 CO C.sub.2
H.sub.5 1-benzyl-3-ethyl-7-nitro-α,β,γ-trimethyl//butyr
icacid 165 CH.sub.3 CH.sub.3 H H 4-n-C.sub.3
H.sub.7 S
##STR110##
CH.sub.2 [CH(C.sub.2 H.sub.5)].sub.2 CO C.sub.2
H.sub.5 1-benzyl-α,β-diethyl-3,3-dimethyl-5-propyl//butyric
acid 166 H H H H 7-OH S
##STR111##
C(CH.sub.3).sub.2 CH.sub.2 C(CH.sub.3).sub.2 CO C.sub.2 H.sub.5
1-benzyl-8-hydroxy-α,α,γ,γ-tetramethyl//butyric
acid 167 CH.sub.3 H CH.sub.3 H 4-OC.sub.2
H.sub.5 S
##STR112##
[C(CH.sub.3).sub.2 ].sub.3 CO C.sub.2
H.sub.5
##STR113##
168 C.sub.2 H.sub.5 H C.sub.2 H.sub.5 C.sub.2
H.sub.5 6-Cl S
##STR114##
CH.sub.2 CH.sub.2 C(C.sub.2 H.sub.5).sub.2 CO C.sub.2
H.sub.5
##STR115##
A mixture of the starting material, tryptophol (32.2 g, 0.2 mole), acetonyl acetate (23.2 g, 0.2 mole) and 3.2 g of p-toluenesulfonic acid in 500 ml of benzene is refluxed for 11/2 hr. in the presence of a Dean-Stark water trap. The benzene solution is washed with 5% sodium bicarbonate, water, dried and evaporated to afford an oil. The oil is subjected to chromatography on a silica gel column using 10% ethyl acetate in benzene as eluent. The acetate, 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-methanol, acetate is obtained as an oil, nmr(CDCl.sub. 3) δ1.52(S,3H), 2.08(S,3H), 4.35(2H).
This acetate is dissolved in 250 ml of methanol and stirred at room temperature. To this solution is added dropwise 20 ml of 10N NaOH. Hydrolysis is immediate. Most of the methanol is removed under reduced pressure, and water is added. The mixture is rendered neutral and extracted with chloroform. The chloroform extract is dried and evaporated to afford the primary alcohol, 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-methanol (X; R1 = CH3, R2, R3, R4, R5 and R6 = H, Y = CH2 and R17 = H), m.p. 145°-147° C., nmr(CDCl.sub. 3) δ1.43(s,3H), 2.68(t, J = 5.5 cps,2H), 3.65 (d, J = 6 cps, 2H), 3.86 (t, J = 5.5 cps, 2H), after crystallization from benzene-petroleum ether.
N,N-dicyclohexylcarbodiimide (17.36 g, 0.084 mole) is added to a cooled, stirred solution of the above primary alcohol (6.09 g, 0.028 mole) in 63 ml of dimethyl sulfoxidebenzene (2:1) containing trifluoroacetic acid (1.12 ml, 0.014 mole) and pyridine (2.24 ml, 0.028 mole). The reaction is stirred at room temperature under nitrogen for 5 hr. The reaction mixture is now diluted with 600 ml of ether, followed by the dropwise addition of a solution of oxalic acid (7.56 g) in 21 ml of methanol. After thirty minutes, water (600 ml) is added and the insoluble material is collected. The organic phase is washed with water (2X), 5% aqueous sodium bicarbonate (2X) and water (2X). After drying (MgSO4) the organic phase is evaporated to yield an oil. The oil is purified by chromatography on silica gel. Elution with 10% ether in benzene affords the title compound as eluate, nmr (CDCl.sub. 3) δ1.59(s,3 H), 2.84(t,J = 5.5 cps, 2H), 4.15(t, J = 5.5 cps, 2H).
Oxidation of the latter compound with silver oxide according to the method of Delepine and Bonnet, cited above, affords 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-carboxylic acid, nmr (CDCl.sub. 3) δ1.79(s,3H), 2.83(t,2H), 4.17(t,2H), 9.20(1H), identical to the product obtained in Example 4.
By following the procedure of Example 169 but using as starting material an equivalent amount of the appropriate starting material of formula II, for example, those described in Examples 1 to 168, inclusive, instead of tryptophol, and using an equivalent amount of the appropriate ketoalcohol lower alkyl ester of formula VIII, then the acid compounds of formula I in which R7 is hydrogen and Z is hydroxy, for example, the respective products of Examples 1 to 168, inclusive, are obtained.
More specifically exemplified, according to the procedure of Example 169 the use of indole-3-ethanethiol and acetonyl acetate affords 1-methyl-1,3,4,9-tetrahydrothiopyrano[3,4-b]indole-1-acetic acid, identical to the product of Example 3. Similarly, the use of tryptophol and 5-acetoxypentan-2-one affords 1-methyl-1,3,4,9-tetrahydropyrano3,4-b]indole-1-propionic acid, identical to the product of Example 2.
To a stirred solution of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid (15 g, 0.061 mole), prepared as described in Example 1, in dry tetrahydrofuran (300 ml), cooled to -5° C, is added triethylamine (18.5 g,0.183 mole), followed by ethyl chloroformate (16.6 g, 0.153 mole). The mixture is stirred at -5° C for 2 hr. This mixture, which now contains the mixed anhydride of the above starting material, is added dropwise to a cooled 40% aqueous solution of the amine, dimethylamine (225 ml). The resulting mixture is stirred at room temperature for one-half hour. Most of the tetrahydrofuran is evaporated, and the residue partitioned between chloroform and water. The organic phase is washed with water, dried over sodium sulfate, and evaporated under reduced pressure. The residue is subjected to chromatography on silica gel. Elution with 20% ethyl acetate in benzene, followed by crystallization of the eluate from ethyl acetate affords the title compound, m.p. 149°-151° C., γ max CHCl.sub. 3 3375, 1634 cm-1.
In the same manner but replacing dimethylamine with an equivalent amount of ammonium hydroxide (concentrated), methylamine (30% aqueous solution), n-hexylamine (20% aqueous solution), diethylamine (30% aqueous solution), or aniline (20% aqueous solution),
1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide, m.p. 158°-160° C,
N,1-dimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide, m.p. 138°-140° C,
N-(hexyl)-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide,
N,n-diethyl-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole1-acetamide, m.p. 99° C, and
N-phenyl-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide, m.p. 205°-208° C, are obtained respectively.
By following the procedure of Example 170 but using as a starting material an equivalent amount of one of the acid compounds of formula I, described in Examples 2 to 168, inclusive, instead of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, and using an equivalent amount of an appropriate amine such as ammonia or a primary or secondary amine described in Example 170, then the corresponding amide compound of formula I [Z = NH2, ##STR116## NHCH3, N(CH3)2, NH(n-C6 H13) or N(C2 H5)2 ] is obtained. Examples of such amide are listed as products in Tables III and IV together with the appropriate starting material and amine used for the preparation of the amide. In each case the starting material is noted by the example in which it is prepared.
TABLE III
__________________________________________________________________________
NO. OF THE EXAMPLE PRODUCT: [(PREFIX LISTED BELOW-
IN WHICH STARTING 1,3,4,9-TETRAHYDROPYRANO[3,4-b]-
EX- MATERIAL IS INDOLE-1-(SUFFIX LISTED BELOW)]
AMPLE
PREPARED AMINE PREFIX//SUFFIX
__________________________________________________________________________
171 2 CH.sub.3 NH.sub.2
N,1-dimethyl// propionamide,
m.p. 149-150° C.
172 2 NH.sub.3
1-methyl//propionamide
173 2 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//propionamide
174 2 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//propionamide
175 2 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-methyl//propionamide
176 4 CH.sub.3 NH.sub.2
N,1-dimethyl//carboxamide
177 4 NH.sub.3
1-methyl//carboxamide, m.p. 188-
189° C.
178 4 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//carboxamide
179 4 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//carboxamide
180 4 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-methyl//carboxamide
181 5 CH.sub.3 NH.sub.2
N,3-dimethyl-1-ethyl//carboxamide
182 8
##STR117##
8-ethyl-1-ethynyl-N-phenyl// carboxamide
183 9 (CH.sub.3).sub.2 NH
1-cyclopropyl-N,N-dimethyl-4-iso-
propyl//carboxamide
184 11 n-C.sub.16 H.sub.13 NH.sub.2
N-hexyl-1-phenyl//carboxamide
185 12 (C.sub.2 H.sub.5).sub.2 NH
1-benzyl-3-methyl-N,N,3-tri-
ethyl//carboxamide
186 14 (CH.sub.3 ).sub.2 NH
N,N,1,4-tetrameethyl//acetamide
187 15 CH.sub.3 NH.sub.2
1-ethyl-N-methyl//acetamide
188 15 NH.sub.3
1-ethyl//acetamide
189 15 (CH.sub.3).sub.2 NH
N,N-dimethyl-1-ethyl//acetamide
190 15 n-C.sub.16 H.sub.13 NH.sub.2
1-ethyl-N-hexyl//acetamide
191 15 (C.sub.2 H.sub.5).sub.2 NH
N,N,1-triethyl//acetamide
192 16 CH.sub.3 NH.sub.2
N-methyl-1-propyl//acetamide
193 16 NH.sub.3
1-propyl//acetamide, m.p. 157.5-
160° C
194 16 (CH.sub.3).sub.2 NH
N,N-dimethyl-1-propyl//acetamide
195 16 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-propyl//acetamide
196 16 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-propyl//acetamide
197 17 CH.sub.3 NH.sub.2
1-isopropyl-N-methyl//acetamide
198 17 NH.sub.3
1-isopropyl//acetamide
199 17 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-isopropyl//acetamide
200 19 CH.sub.3 NH.sub.2
N,3-dimethyl-1-propyl//acetamide
201 19
##STR118##
3-methyl-N-phenyl-1-propyl// acetamide
202 19 (CH.sub.3).sub.2 NH
1-propyl-N,N,3-trimethyl//acetamide
203 19 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-3-methyl-1-propyl//
acetamide
204 19 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-3-methyl-1-propyl//
acetamide
205 21 CH.sub.3 NH.sub.2
N,α,1-trimethyl//acetamide
206 21 NH.sub.3
α,1-dimethyl//acetamide
207 21 (CH.sub.3).sub.2 NH
N,N,α,1-tetramethyl//acetamide
208 21 n-C.sub.6 H.sub.13 NH.sub.2
α,1-dimethyl-N-hexyl//acetamide
209 21 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-α,1-dimethyl//
acetamide
210 22 CH.sub.3 NH.sub.2
1-cyclohexyl-N,α,α-trimethyl//
acetamide
211 23 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-phenyl//acetamide
212 26 CH.sub.3 NH.sub.2
N,8-dimethyl-1-propyl//acetamide
213 31 NH.sub.3
6-benzyloxy-1-methyl//acetamide
214 32 (CH.sub.3).sub.2 NH
1-propyl-N,N,5-trimethyl//
acetamide
215 38 n-C.sub.6 H.sub.13 NH.sub.2
1-cyclopropyl-α,α-diethyl-3,3-
dimethyl-6-ethoxy-N-hexyl//
acetamide
216 43 (CH.sub.3).sub.2 NH
1-benzyl-N,N,α,α,3-pentamethyl-
8-propionoxy//acetamide
217 46 CH.sub.3 NH.sub.2
5-iodo-1-isopropyl-N-methyl//
propionamide
218 49 NH.sub.3
1-cyclobutyl-3-methyl-8-nitro-
α-propyl//propionamide
219 54 (CH.sub.3).sub.2 NH
4,4-diethyl-N,N,α,α,β,3-hexa-
7
methyl-1-methallyl//propionamide
220 57 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-5-methoxy-α-methyl-
1-phenyl-3-propyl//propionamide
221 62 CH.sub.3 NH.sub.2
N-methyl-β-propyl-1-(1-propynyl)-
3,3,5-triethyl//propionamide
222 63
##STR119##
1-cyclopropyl-α,β-diethyl-6-
ethoxy-N-phenyl//propionamide
223 67 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//butyramide
224 67 CH.sub.3 NH.sub.2
N,1-dimethyl//butyramide
225 67 NH.sub.3
1-methyl//butyramide
226 67 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//butyramide
227 70 CH.sub.3 NH.sub.2
β,γ,γ,4-tetrapropyl-N,3,3-
trimethyl-1-vinyl//butyramide
228 71 (C.sub.2 H.sub.5).sub.2 NH
1-allyl-N,N-diethyl-β,β,γ,.gam
ma.
tetramethyl//butyramide
229 73 (CH.sub.3).sub.2 NH
N,N,α,α,β,β,γ,.gam
ma.,4,5-decamethyl-
1-ethynyl//butyramide
230 76 NH.sub.3
5-bromo-1-cyclopentyl-α,α,β-
trimethyl//butyramide
231 78 CH.sub.3 NH.sub.2
8-ethyl-N,α-dimethyl-1-phenyl//
butyramide
232 80 (C.sub.2 H.sub.5).sub.2 NH
1-phenyl-N,N,α,γ-tetraethyl-
3,3,5-trimethyl//butyramide
233 82 n-C.sub.6 H.sub.13 NH.sub.2
1-benzyl-α,β-diethyl-3,3-
dimethyl-N-hexyl-5-propyl//
butyramide
__________________________________________________________________________
TABLE IV
__________________________________________________________________________
NO. OF THE EXAMPLE PRODUCT: [(PREFIX LISTED BELOW-
IN WHICH STARTING 1,3,4,9-TETRAHYDROTHIOPYRANO-
MATERIAL IS [3,4-b]INDOLE-1-(SUFFIX LISTED
EXAMPLE PREPARED AMINE BELOW)] PREFIX/SUFFIX
__________________________________________________________________________
234 3 CH.sub.3 NH.sub.2
N,1-dimethyl//acetamide
235 3 NH.sub.3 1-methyl//acetamide
236 3 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//acetamide
237 3 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//acetamide, m.p.
182 - 184° C
238 3 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-methyl//acetamide
239 129 CH.sub.3 NH.sub.2
N,1-dimethyl//propionamide
240 129 NH.sub.3 1-methyl//propionamide
241 129 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//propionamide
242 129 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//propionamide
243 129 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-methyl//propion-
amide
244 87 CH.sub.3 NH.sub.2
N,1-dimethyl//carboxamide
245 87 NH.sub.3 1-methyl//carboxamide,
246 87 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//carboxamide
247 87 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//carboxamide
248 87 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-methyl//carboxamide
249 88 CH.sub.3 NH.sub.2
N,3-dimethyl-1-ethyl//carboxamide
250 91 NH.sub.3 8-ethyl-1-ethynyl//carboxamide
251 92 (CH.sub.3).sub.2 NH
1-cyclopropyl-N,N-dimethyl-4-iso-
propyl//carboxamide
252 94 n-C.sub.16 H.sub.13 NH.sub.2
N-hexyl-1-phenyl//carboxamide
253 95 (C.sub.2 H.sub.5).sub.2 NH
1-benzyl-3-methyl-N,N,3-tri-
ethyl//carboxamide
254 97 (CH.sub.3).sub.2 NH
N,N,1,4-tetramethyl//acetamide
255 98 CH.sub.3 NH.sub.2
1-ethyl-N-methyl//acetamide
256 98 NH.sub.3 1-ethyl//acetamide
257 98 (CH.sub.3).sub.2 NH
N,N-dimethyl-1-ethyl//acetamide
258 98 n-C.sub.16 H.sub.13 NH.sub.2
1-ethyl-N-hexyl//acetamide
259 98 (C.sub.2 H.sub.5).sub.2 NH
N,N,1-triethyl//acetamide
260 99 CH.sub.3 NH.sub.2
N-methyl-1-propyl//acetamide
261 99 NH.sub.3 1-propyl//acetamide
262 99 (CH.sub.3).sub.2 NH
N,N-dimethyl-1-propyl//acetamide
263 99 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-propyl//acetamide
264 99 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-propyl//acetamide
265 100 CH.sub.3 NH.sub.2
1-isopropyl-N-methyl//acetamide
266 100 NH.sub.3 1-isopropyl//acetamide
267 100 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-isopropyl//acetamide
268 102 CH.sub.3 NH.sub.2
N,3-dimethyl-1-propyl//acetamide
269 102 NH.sub.3 3-methyl-1-propyl//acetamide
270 102 (CH.sub.3).sub.2 NH
1-propyl-N,N,3-trimethyl//
acetamide
271 102 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-3-methyl-1-propyl//
acetamide
272 102 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-3-methyl-1-propyl//
acetamide
273 104 CH.sub.3 NH.sub.2
N,α,1-trimethyl//acetamide
274 104 NH.sub.3 α,1-dimethyl//acetamide
275 104 (CH.sub.3).sub.2 NH
N,N,α-1-tetramethyl//acetamide
276 104 n-C.sub.6 H.sub.13 NH.sub.2
α,1-dimethyl-N-hexyl//acetamide
277 104 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-α,1-dimethyl//
acetamide
278 105 CH.sub.3 NH.sub.2
1-cyclohexyl-N,α,α-trimethyl/
/
acetamide
279 106 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1-phenyl//acetamide
280 109 CH.sub.3 NH.sub.2
N,8-dimethyl-1-propyl//acetamide
281 111 NH.sub.3 6-bromo-1-propyl//acetamide
282 117 (CH.sub.3).sub.2 NH
α,α-diethyl-N,N-dimethyl-8-fl
uoro-
1-vinyl//acetamide
283 121 n-C.sub.6 H.sub.13 NH.sub.2
1-cyclopropyl-α,α-diethyl-3,3
-
dimethyl-6-ethoxy-N-hexyl//
acetamide
284 126 (CH.sub.3).sub.2 NH
1-benzyl-N,N,α,α,3-pentamethy
l-
8-propionoxy//acetamide
285 128 CH.sub.3 NH.sub.2
1-(2-thienyl)-N,α,α-trimethyl
//
acetamide
286 132 NH.sub.3 1-cyclobutyl-3-methyl-8-nitro-
α-propyl//propionamide
287 137 (CH.sub.3).sub.2 NH
4,4-diethyl-N,N,α,α,β,3-
hexamethyl-1-methallyl//
propionamide
288 140 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-5-methoxy-α-methyl-1-
phenyl-3-propyl//propionamide
289 145 CH.sub.3 NH.sub.2
N-methyl-β-propyl-1-(1-propynyl)-
3,3,5-triethyl//propionamide
290 146
##STR120##
1-cyclopropyl-α,β-diethyl-6-
ethoxy-N-phenyl//propionamide
291 150 (CH.sub.3).sub.2 NH
N,N,1-trimethyl//butyramide
292 150 CH.sub.3 NH.sub.2
N,1-dimethyl//butyramide
293 150
##STR121##
1-methyl-N-phenyl//butyramide
294 150 n-C.sub.6 H.sub.13 NH.sub.2
N-hexyl-1-methyl//butyramide
295 153 CH.sub.3 NH.sub.2
β,γ,γ,4-tetrapropyl-N,3,
3-
trimethyl-1-vinyl//butyramide
296 154 (C.sub.2 H.sub.5).sub.2 NH
1-allyl-N,N-diethyl-β,β,γ
,γ-
tetramethyl//butyramide
297 155 (CH.sub. 3).sub.2 NH
7-chloro-N,N-dimethyl-α,β,.bet
a.,γ,γ-
4,4-heptaethyl-1-ethynyl//butyramide
298 159 NH.sub.3 5-bromo-1-cyclopentyl-α,α,.be
ta.-
trimethyl//butyramide
299 161 CH.sub.3 NH.sub.2
N,α-dimethyl-8-ethyl-1-phenyl//
butyramide
300 163 (C.sub.2 H.sub.5).sub.2 NH
1-phenyl-N,N,α,γ-tetraethyl-
3,3,5-trimethyl//butyramide
301 165 n-C.sub.6 H.sub.13 NH.sub.2
1-benzyl-α,β-diethyl-3,3-dimet
hyl- - N-hexyl-5-propyl//butyramide
302 168 CH.sub.3 NH.sub.2
7-chloro-N-methyl-α,α,3,4,4-
pentaethyl-1-(2-thienyl)//
butyramide
__________________________________________________________________________
By following the procedure of Example 1 but using an equivalent amount of pyruvamide instead of ethyl acetoacetate, 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-carboxamide, m.p. 188°- 189° C. after recrystallization from benzene-hexane, identical with the product of Example 177, is obtained.
In the same manner but using an equivalent amount of the appropriate starting material of formula II in place of tryptophol together with the appropriate α-, β-, γ- or δ-ketoamide, the products listed in Tables III and IV may be obtained. For example, by using tryptophol (II; R2, R3, R4, R5, R6 = H and X' = OH) and the β-ketoamide, N,N-dimethyl-acetoacetamide, in the procedure of this Example, N,N,1-trimethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetamide, identical with the product of Example 170, is obtained.
1-Methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid (10 g., 0.04 mole), prepared as described in Example 1, in 150 ml. of tetrahydrofuran is added dropwise to a stirred suspension of sodium hydride (4.4 g. of 55% dispresion) in 200 ml. of tetrahydrofuran. This mixture is heated at 50° C. with stirring for 2 hr. Methyl iodide (14.2 g. 0.1 mole) is added dropwise and heating and stirring is continued for a further 2 hr.
After cooling, water is added until the solution is clear. The tetrahydrofuran is evaporated off under reduced pressure, the residue is partition between water and benzene. The aqueous phase is washed once with benzene, made acidic with HCl, and extracted with benzene (3x). The organic phase is washed with water, dried over sodium sulfate and treated with charcoal. The organic layer is evaporated. The residue is crystallized from benzene and then ether-petroleum ether to afford the title compound, m.p. 105°-108° C., nmr (CDCl3) δ 1.73 (S,3H), 2.83 (t, J = 5.5 2H), 3.0 (2H), 3.68 (3H), 4.08 (t, J = 5.5, 2H), 7.34 (4H), 9.47 (1H).
In the same manner but replacing methyl iodide with an equivalent amount of ethyl iodide, or propyl iodide 9-ethyl-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, m.p. 134°- 136° C., and 1-methyl-9-propyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid, m.p. 120°-122° C., are obtained, respectively. The corresponding ethyl ester of the latter compound, 1-methyl-9-propyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid ethyl ester has m.p. 72°-74° C.
By following the procedure of Example 304 but using the starting material an equivalent amount of the acid compounds of formula I, compounds of formula I in which R7 is hydrogen and Z is hydroxy, described in Examples 1 to 168, inclusive, instead of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid, and using an equivalent amount of an appropriate lower alkyl or lower alkenyl halide, then the corresponding N-alkylated acid compounds of formula I in which R7 is lower alkyl or lower alkenyl are obtained. Examples of these latter compounds are listed as products in Tables V and VI together with the appropriate starting material and alkyl or alkynyl halide used for their preparation. In each case the starting material is noted by the Example in which it is prepared.
TABLE V
__________________________________________________________________________
NO. OF THE EXAMPLE PRODUCT: [(PREFIX LISTED BELOW-
IN WHICH STARTING 1,3,4,9-TETRAHYDROPYRANO[3,4-b]-
MATERIAL IS ALKYL OR ALKENYL
INDOLE-1-(SUFFIX LISTED BELOW)]
EXAMPLE PREPARED HALIDE PREFIX//SUFFIX
__________________________________________________________________________
305 1 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-methyl//acetic acid,
m.p.103 - 105° C.
306 1 CH.sub.2 ═CHBr
1-methyl-9-vinyl//acetic acid
307 1 CH.sub.2 ═C(CH.sub.3)CH.sub.2 Br
1-methyl-9-methallyl//acetic acid
308 2 n-C.sub.3 H.sub.7 I
1-methyl-9-propyl//propionic acid
309 2 CH.sub.3 I 1,9-dimethyl//propionic acid, m.p.
129 - 130° C
310 2 CH.sub.2 ═CHBr
1-methyl-9-vinyl//propionic acid
311 2 CH.sub.2 ═CHCH.sub.2 Cl
9-allyl-1-methyl//propionic acid
312 4 CH.sub.3 I 1,9-dimethyl//carboxylic acid
313 4 CH.sub.2 ═CHBr
1-methyl-9-vinyl//carboxylic acid
314 7 CH.sub.3 I 6-hydroxy-1-(1-propenyl)-3,3,9-
trimethyl//carboxylic acid
315 9 CH.sub.3 CH═CHBr
1-cyclopropyl-4-isopropyl-9-
(1-propenyl)//carboxylic acid
316 11 i-C.sub.3 H.sub.7 I
9-isopropyl-1-phenyl//carboxylic
acid
317 15 CH.sub.3 I 1-ethyl-9-methyl//acetic acid
318 15 C.sub.2 H.sub.5 Cl
1,9-diethyl//acetic acid
319 15 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-ethyl//acetic acid
320 15 CH.sub.2 ═CHBr
1-ethyl-9-vinyl//acetic acid
321 16 CH.sub.3 I 9-methyl-1-propyl//acetic acid
322 16 n-C.sub.3 H.sub.7 Cl
1,9-dipropyl//acetic acid
323 16 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-propyl//acetic acid
324 16 CH.sub.2 ═C(CH.sub.3)CH.sub.2 Br
9-methallyl-1-propyl//acetic acid
325 17 CH.sub.3 I 9-methyl-1-isopropyl//acetic acid
326 17 CH.sub.2 ═CHBr
1-isopropyl-9-vinyl//acetic acid
327 19 n-C.sub.3 H.sub.7 Cl
1,9-dipropyl-3-methyl//acetic acid
328 19 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-3-methyl-1-propyl//acetic
acid
329 21 CH.sub.3 I α,1,9-trimethyl//acetic acid
330 21 CH.sub.2 ═CHBr
α,1-dimethyl-1-vinyl//acetic
acid
331 22 n-C.sub.3 H.sub.7 Cl
1-cyclohexyl-α,α-dimethyl-
9-
propyl//acetic acid
332 27 CH.sub.2 ═CHCH.sub.2 I
9-allyl-1-(2-thienyl)//acetic acid
333 29 CH.sub.3 Cl 1,9-dimethyl-6-methoxy//acetic acid
334 34 CH.sub.2 ═CHBr
6-nitro-1-propyl-9-vinyl//
acetic acid
335 40 C.sub.2 H.sub.5 Cl
α,3-dimethyl-9-ethyl-1-phenyl-
4,4,5-tripropyl//acetic acid
336 42 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-benzyl-α,α-diiso
propyl-
3,3,4,4,5-pentaethyl//acetic acid
337 48 C.sub.2 H.sub.5 I
7-hydroxy-1-(2-propynyl)-β,β
,9-
triethyl//propionic acid
338 49 CH.sub.3 I 1-cyclobutyl-3,9-dimethyl-8-nitro-
Ε-propyl//propionic acid
339 54 CH.sub.2 ═C(CH.sub.3 CH.sub.2 Cl
4,4-diethyl-1,9-dimethally-α,.al
pha.,β,-
3-tetramethyl//propionic acid
340 59 CH.sub.2 ═CHCH.sub. 2 Br
9-allyl-8-chloro-β,3,3,4,4-
pentamethyl-1-(2-thienyl)//
propionic acid
341 60 CH.sub.2 ═CHCl
1-methyl-6-nitro-α,α,.beta
.,β,3-penta-
ethyl-9-vinyl//propionic acid
342 63 C.sub.2 H.sub.5 Cl
1-cyclopropyl-6-ethoxy-α,β,
9-
triethyl//propionic acid
343 67 CH.sub.3 I 1,9-dimethyl//butyric acid
344 67 CH.sub.2 ═CHCH.sub.2 Cl
9-allyl-1-methyl//butyric acid
345 68 C.sub.2 H.sub.5 Cl
1,9-diethyl-γ,3-dimethyl//butyri
c
acid
346 70 CH.sub.2 ═CHBr
3,3-dimethyl-1,9-divinyl-β,.gamma
.,γ,-
4-tetrapropyl//butyric acid
347 72 CH.sub.2 ═CHBr
7-chloro-1,9-divinyl-α,β,.b
eta.,γ,γ-
4-heptaethyl//butyric acid
348 78 C.sub.2 H.sub.5 I
8,9-diethyl-α-methyl-1-phenyl//
butyric acid
349 82 CH.sub.3 I 1-benzyl-α,β-diethyl-5-prop
yl- - 3,3,9-trimethyl//butyric
acid
350 85 C.sub.2 H.sub.5 Br
7-chloro-α,α,3,4,4,9-hexae
thyl-
1-(2-thienyl)//butyric
__________________________________________________________________________
acid
TABLE VI
__________________________________________________________________________
NO. OF THE EXAMPLE PRODUCT: [(PREFIX LISTED BELOW-1,3-
IN WHICH STARTING 4,9-TETRAHYDROTHIOPYRANO[3,4-b]-
MATERIAL IS ALKYL OR ALKENYL
INDOLE-1-(SUFFIX LISTED BELOW)]
EXAMPLE PREPARED
HALIDE PREFIX//SUFFIX
__________________________________________________________________________
351 3 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-methyl//acetic acid
352 3 CH.sub.3 I 1,9-dimethyl//acetic acid
353 3 CH.sub.2 ═C(CH.sub.3)CH.sub.2 Br
1-methyl-9-methallyl//acetic
acetic acid
354 129 n-C.sub.3 H.sub.7 I
1-methyl-9-propyl//propionic
acid
355 129 CH.sub.3 I 1,9-dimethyl//propionic acid
356 129 CH.sub.2 ═CHBr
1-methyl-9-vinyl//propionic acid
357 129 CH.sub.2 ═CHCH.sub.2 Cl
9-allyl-1-methyl//propionic acid
358 87 CH.sub.3 I 1,9-dimethyl//carboxylic acid
359 87 CH.sub.2 ═CHBr
1-methyl-9-vinyl//carboxylic
acid
360 90 CH.sub.3 I 6-hydroxy-1-(1-propenyl)-3,3,9-
trimethyl//carboxylic acid
361 92 CH.sub.3 CH═CHBr
1-cyclopropyl-4-isopropyl-9-
(1-propenyl)//carboxylic acid
362 94 2-C.sub.3 H.sub.7 I
9-isopropyl-1-phenyl//carboxylic
acid
363 98 CH.sub.3 I 1-ethyl-9-methyl//acetic acid
364 98 C.sub.2 H.sub.5 Cl
1,9-diethyl//acetic acid
365 98 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-ethyl//acetic acid
366 98 CH.sub.2 ═CHBr
1-ethyl-9-vinyl//acetic acid
367 99 CH.sub.3 I 9-methyl-1-propyl//acetic acid
368 99 n-C.sub.3 H.sub.7 Cl
1,9-dipropyl//acetic acid
369 99 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-propyl//acetic acid
370 99 CH.sub.2 ═C(CH.sub.3)CH.sub.2 Br
9-methyl-1-propyl//acetic
acid
371 100 CH.sub.3 I 9-methyl-1-isopropyl//acetic
acid
372 100 CH.sub.2 ═CHBr
1-isopropyl-9-vinyl//acetic
acid
373 102 n-C.sub.3 H.sub.7 Cl
1,9-dipropyl-3-methyl//acetic
acid
374 102 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-3-methyl-1-propyl//
acetic acid
375 104 CH.sub.3 I α,1,9-trimethyl//acetic acid
376 104 CH.sub.2 ═CHBr
α,1-dimethyl-1-vinyl//acetic
acid
377 105 n-C.sub.3 H.sub.7 Cl
1-cyclohexyl-α,α-dimethyl-
9-
propyl//acetic acid
378 110 CH.sub.2 ═CHCH.sub.2 I
9-allyl-1-(2-thienyl)//acetic
acid
379 112 CH.sub.3 Cl 1,9-dimethyl-6-methoxy//
acetic acid
380 117 CH.sub.2 ═CHBr
α,α-diethyl-1,9-divinyl-8-
fluoro//acetic acid
381 123 C.sub.2 H.sub.5 Cl
α,3-dimethyl-9-ethyl-1-phenyl-
4,4,5-tripropyl//acetic
acid
382 125 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-1-benzyl-α,α-
diisopropyl-3,3,4,4,5-
pentaethyl//acetic acid
383 131 C.sub.2 H.sub.5 I
7-hydroxy-1-(2-propynyl)-
β,β,9-triethyl//propionic
acid
384 132 CH.sub.3 I 1-cyclobutyl-3,9-dimethyl-8-
nitro-α-propyl//propionic acid
385 137 CH.sub.2 ═C(CH.sub.3)CH.sub.2 Cl
4,4-diethyl-1,9-dimethallyl-
α,α,β,3-tetramethyl//
propionic
acid
386 142 CH.sub.2 ═CHCH.sub.2 Br
9-allyl-8-chloro-β,3,3,4,4-
pentamethyl-1-(2-thienyl)//
propionic acid
387 143 CH.sub.2 ═CHCl
1-methyl-6-nitro-α,α,.beta
.,β,3-penta-
ethyl-9-vinyl//propionic acid
388 146 C.sub.2 H.sub.5 Cl
1-cyclopropyl-6-ethoxy-α,β,
9-
triethyl//propionic acid
389 150 CH.sub.3 I 1,9-dimethyl//butyric acid
390 150 CH.sub.2 ═CHCH.sub.2 Cl
9-allyl-1-methyl//butyric acid
391 151 C.sub.2 H.sub.5 Cl
1,9-diethyl-γ,3-dimethyl//
butyric acid
392 153 CH.sub.2 ═CHBr
3,3-dimethyl-1,9-divinyl-β,.gamma
.,γ,-
4-tetrapropyl//butyric acid
393 155 CH.sub.2 ═CHBr
7-chloro-1,9-divinyl-α,β,.b
eta.,γ,γ,-
4,4-heptaethyl//butyric acid
394 161 C.sub.2 H.sub.5 I
8,9-diethyl-α-methyl-1-phenyl//
butyric acid
395 165 CH.sub.3 I 1-benzyl-α,β-diethyl-5-prop
yl-
3,3,9-trimethyl//butyric acid
396 168 C.sub.2 H.sub.5 Br
7-chloro-α,α,3,4,4,9-hexae
thyl-
1-(2-thienyl)//butyric
__________________________________________________________________________
acid
By following the procedure of Example 304 but using as the starting material an equivalent amount of the ester compounds of formula I in which R7 is hydrogen and Z is lower alkoxy, obtained prior to hydrolysis in Example 1 and 3 to 168, inclusive, instead of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid, and using an equivalent amount of an appropriate lower alkyl or lower alkenyl halide, then the corresponding N-alkylated ester compounds of formula I in which R7 is lower alkyl or lower alkenyl, are obtained.
For example, when following the procedure of Example 304, the replacement of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid by an equivalent amount of its corresponding ethyl ester, described in Example 1, and then use the same alkyl halide, methyl iodide, affords 1,9-dimethyl-1,3,4,9-tetrahydropyrano[3,4 -b]indole-1-acetic acid ethyl ester.
Similarly, the replacement of 1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid by an equivalent amount of 1-methyl-1,3,4,9-tetrahydrothiopyrano[3,4-b]indole1-acetic acid methyl ester, described in Example 3, affords 1,9-dimethyl-1,3,4,9-tetrahydrothiopyrano[3,4b]indole-1-acetic acid methyl ester.
By following the procedure of Example 170 but using as the starting material an equivalent amount of one of the N-alkylated acid compounds of formula I, described in Examples 304 to 396, inclusive, instead of 1-methyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid, and using an equivalent amount of an appropriate amine such as ammonia or a primary or secondary amine, described in Example 170, then the corresponding amide compound of formula I in which R7 is lower alkyl or lower alkenyl and Z is amino, lower alkyl amino, di(lower)alkylamino or phenylamino, is obtained. Examples of such amides are listed as products in Tables VII and VIII together with the appropriate starting material, noted by the example in which it is prepared, and the amine used for the preparation of the amide.
TABLE VII
__________________________________________________________________________
NO. OF THE EXAMPLE PRODUCT:[(PREFIX LISTED BELOW-
IN WHICH STARTING 1,3,4,9-TETRAHYDROPYRANO[3,4-b]-
MATERIAL IS INDOLE-1-(SUFFIX LISTED BELOW)]
EXAMPLE PREPARED AMINE PREFIX//SUFFIX
__________________________________________________________________________
398 304 (CH.sub.3).sub.2 NH
N,N,1,9-tetramethyl//acetamide,
ν.sub.max.sup.CHCl 1620, 1070 cm.sup.-1,
nmr
(CDCl.sub.3) δ 1.71, 2.76, 2.89,
3.00,
3.71
399 304 CH.sub.3 NH.sub.2
N,1,9-trimethyl//acetamide, m.p.
136 - 138° C.
400 304 NH.sub.3
1,9-dimethyl//acetamide, m.p.
105 - 106° C.
401 304 n-C.sub.6 H.sub.13 NH.sub.2
1,9-dimethyl-N-hexyl//acetamide
402 304 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1,9-dimethyl//
acetamide, ν.sub.max.sup.CHCl.sbsp.3 1630
cm.sup.-1,
nmr (CDCl.sub.3) δ 1.10, 1.74, 2.80,
3.97
403 305 CH.sub.3 NH.sub.2
9-allyl-N,1-dimethyl//acetamide
404 305 (CH.sub.3).sub.2 NH
9-allyl-N,N,1-trimethyl//
acetamide
405 309 CH.sub.3 NH.sub.2
N,1,9-trimethyl//propionamide,
m.p. 148-150° C
406 309 (C.sub.2 H.sub. 5).sub.2 NH
1,9-dimethyl-N,N-diethyl//
propionamide
407 311 NH.sub.3
9-allyl-1-methyl//propionamide
408 311 (CH.sub.3).sub.2 NH
9-allyl-N,N,1-trimethyl//
propionamide
409 313 CH.sub.3 NH.sub.2
N,1-dimethyl-9-vinyl//
carboxamide
410 314 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-6-hydroxy-1-
(1-propenyl)-3,3,9-trimethyl//
carboxamide
411 316 n-C.sub.6 H.sub.3 NH.sub.2
N-hexyl-9-isopropyl-1-phenyl//
carboxamide
412 317 CH.sub.3 NH.sub.2
N,9-dimethyl-1-ethyl//acetamide
413 319 (C.sub.2 H.sub.5).sub.2 NH
9-allyl-N,N,1-triethyl//
acetamide
414 320 (CH.sub.3).sub.2 NH
N,N-dimethyl-1-ethyl-9-vinyl//
acetamide
415 321 CH.sub.3 NH.sub.2
N,9-dimethyl-1-propyl//
acetaide
416 323 (C.sub.2 H.sub.5).sub.2 NH
9-allyl-N,N-diethyl-1-propyl//
acetamide
417 331 CH.sub.3 NH.sub.2
1-cyclohexyl-9-propyl-N,α,α-
trimethyl//acetamide
418 332 n-C.sub.6 H.sub.13 NH.sub.2
9-allyl-N-hexyl-1-(2-thienyl)//
acetamide
419 333 (CH.sub.3).sub.2 NH
6-methoxy-N,N,1,9-tetramethyl//
acetamide, m.p. 118-120° C.
420 335 CH.sub.3 NH.sub.2
9-ethyl-1-phenyl-4,4,5-
tripropyl-N,α,3-trimethyl//
acetamide
421 341 (C.sub.2 H.sub.5).sub.2 NH
N,N,α,α,β,β,3-heptaethy
l-1-
methyl-6-nitro-9-vinyl//
propionamide
422 342 (C.sub.2 H.sub.5).sub.2 NH
1-cyclopropyl-6-methoxy-N,N,-
α,β,9-pentaethyl-9-vinyl//
propionamide
423 343 CH.sub.3 NH.sub.2
N,1,9-trimethyl//butyramide
424 344 (CH.sub.3).sub.2 NH
9-allyl-N,N,1-trimethyl//
butyramide
425 345 NH.sub.3
1,9-diethyl-γ,3-dimethyl//
butyramide
426 349 CH.sub.3 NH.sub.2
1-benzyl-α,β-diethyl-5-propyl-
N,3,3,9-tetramethyl//
butyramide
__________________________________________________________________________
TABLE VIII
__________________________________________________________________________
NO. OF THE EXAMPLE PRODUCT:[(PREFIX LISTED BELOW-1,3,
IN WHICH STARTING 4,9-TERRAHYDROTHIOPYRANO[3,4-b]-
MATERIAL IS INDOLE-1-(SUFFIX LISTED BELOW)]
EXAMPLE PREPARED AMINE PREFIX//SUFFIX
__________________________________________________________________________
427 352 (CH.sub.3).sub.2 NH
N,N,1,9-tetramethyl//acetamide,
ν.sub.max.sup.CHCl.sbsp.3 1625 cm, nmr
(CDCl.sub.3),
δ 2.23, 3,65
428 352 CH.sub.3 NH.sub.2
N,1,9-trimethyl//acetamide, m.p.
127-128° C.
429 352 NH.sub.3
1,9-dimethyl//acetamide
430 352 n-C.sub.6 H.sub.13 NH.sub.2
1,9-dimethyl-N-hexyl//acetamide
431 352 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-1,9-dimethyl//
acetamide
432 351 CH.sub.3 NH.sub.2
9-allyl-N,1-dimethyl//acetamide
433 351 (CH.sub.3).sub.2 NH
9-allyl-N,N,1-trimethyl//
acetamide
434 355 CH.sub.3 NH.sub.2
N,1,9-trimethyl//propionamide
435 355 (C.sub.2 H.sub.5).sub.2 NH
1,9-dimethyl-N,N-diethyl//
propionaide
436 357 NH.sub.3
9-allyl-1-methyl//propionamide
437 357 (CH.sub.3).sub.2 NH
9-allyl-N,N,1-trimethyl//
propionamide
438 359 CH.sub.3 NH.sub.2
N,1-dimethyl-9-vinyl//
carboxamide
439 360 (C.sub.2 H.sub.5).sub.2 NH
N,N-diethyl-6-hydroxy-1-
(1-propenyl)-3,3,9-trimethyl//
carboxamide
440 362 n-C.sub.6 H.sub.3 NH.sub.2
N-hexyl-9-isopropyl-1-phenyl//
carboxamide
441 363 CH.sub.3 NH.sub.2
N,9-dimethyl-1-ethyl//
acetamide
442 365 (CH.sub.2 H.sub.5).sub.2 NH
9-allyl-N,N,1-triethyl//
acetamide
443 366 (CH.sub.3).sub.2 NH
N,N-dimethyl-1-ethyl-9-vinyl//
acetamide
444 367 CH.sub.3 NH.sub.2
N,9-dimethyl-1-propyl//acetamide
445 369 (C.sub.2 H.sub.5).sub.2 NH
9-allyl-N,N-diethyl-1-propyl//
acetamide
446 377 CH.sub.3 NH.sub.2
1-cyclohexyl-9-propyl-N,α,α-
trimethyl//acetamide
447 378 n-C.sub.6 H.sub.13 NH.sub.2
9-allyl-N-hexyl-1-(2-thienyl)//
acetamide
448 379 (CH.sub.3).sub.2 NH
6-methoxy-N,N,1,9-tetramethyl//
acetamide
449 381 CH.sub.3 NH.sub.2
9-ethyl-1-phenyl-4,4,5-
tripropyl-N,α,3-trimethyl//
acetamide
450 387 (C.sub.2 H.sub.5).sub.2 NH
N,N,α,α,β,β,3-heptaethy
l-1-
methyl-6-nitro-9-vinyl//
propionamide
451 388 (C.sub.2 H.sub.5).sub.2 NH
1-cyclopropyl-6-ethoxy-N,N,-
α,β,9-pentaethyl//propionamide
452 389 CH.sub.3 NH.sub.2
N,1,9-trimethyl//butyramide
453 390 (CH.sub.3).sub.2 NH
9-allyl-N,N,1-trimethyl//
butyramide
454 391 NH.sub.3
1,9-diethyl-γ,3-dimethyl//
butyramide
455 395 CH.sub.3 NH.sub.2
1-benzyl-α,β -diethyl-5-propyl-
N,3,3,9-tetramethyl//butyramide
__________________________________________________________________________
A mixture of 6-benzyloxy-1-methyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid (5.3 g., 0.015 mole), prepared as described in Example 31, in 250 ml. of anhydrous ethanol, and 1.1 g. of 10% palladium on carbon is stirred at room temperature under a hydrogen atmosphere until no more hydrogen is being taken up by the reaction mixture. The catalyst is removed by filtration through diatomaceous earth (Celite) and the filtrate concentrated. The residue is recrystallized from ethanol-benzene to afford the title compound, m.p. 170°-171° C.
The corresponding benzylamine salt is prepared by the mixing of equimolar ethereal solutions of benzylamine and the above product. The resulting solid is recrystallized from acetonitrile to afford 6-hydroxy-1-methyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid benzylamine salt, m.p. 191°-193° C. The corresponding acetate is prepared by allowing a mixture of the title compound and a five molar excess of acetic anhydride in pyridine solution to stand for 24 hr. Dilution of the mixture with water extraction with ether and recrystallization of the extract residue from benzene-petroleum ether, affords 6-acetoxy-1-methyl-1,3,4,9-tetrahydro[3,4-b]indole-1-acetic acid, identical with the product of Example 30.
Table IX provides further examples of the compounds of this invention. The remarks relating to procedure, starting material and product applied to Table I are applicable also to Table IX. Note also that starting materials of both formulae II and IIa are utilized.
TABLE IX
__________________________________________________________________________
PRODUCT:
KETOESTER [(PREFIX LISTED
OF BELOW)-1,3,4,9-
FORMULA TETRAHYDROPYRANO-
VI [3,4-b]INDOLE-1-
STARTING MATERIAL OF FORMULA IIa
##STR122## (SUFFIX LISTED BELOW)]
EX.
R.sup.2
R.sup.3
R.sup.4
R.sup.5
R.sup.6 X R.sup.1 Y R.sup.16
PREFIX//SUFFIX
__________________________________________________________________________
457
H H CH.sub.3
H H O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
4-methyl-1-propyl//
acetic acid, m.p.
191-195° C.
458
H H H H 5-CH.sub.3 O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
6-methyl-1-propyl//
acetic acid, m.p.
126-129° C.
459
H H H H 4-i-C.sub.3 H.sub.7
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
5-isopropyl-1-propyl//
acetic acid, m.p.
164.5-165° C.
460
H H H H 4-Cl O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
5-chloro-1-propyl//
acetic acid, m.p.
166-169° C.
461
H H H H 6-OCH.sub.3
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
7-methoxy-1-propyl//
acetic acid, m.p.
164-166° C.
462
H H CH.sub.3
H H O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-4-methyl//
acetic acid, m.p.
153-156° C.,
(Isomer A), m.p.
132-133° C
(Isomer B)
463
H H H H 4-Cl O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
5-chloro-1-methyl//
acetic acid, m.p.
183-184° C.
464
H H H H 4-C.sub.2 H.sub.5
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
5-ethyl-1-propyl//
acetic acid, m.p.
130-131° C.
465
H CH.sub.3
H H H O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-3-methyl//
acetic acid, m.p.
147-148° C.,
(Isomer A), m.p.
145-146° C.,
(Isomer B)
466
H H H H 4-CH.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-5-methyl//
acetic acid, m.p.
170-172° C.
467
H H H H 4-CH.sub.3 O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
1,5-dimethyl//acetic
acid, m.p.
150-151° C.
468
H H H H 4-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
5-chloro-1-ethyl//
acetic acid, m.p.
154-157° C.
469
H H CH.sub.3
H H O t-C.sub.4 H.sub.9
CH.sub.2 CO
C.sub.2 H.sub.5
1-t-butyl-4-methyl//
acetic acid, m.p.
179-181° C.
470
H H H H 4-OCH.sub.3
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
5-methoxy-1-propyl//
acetic acid, m.p.
148-151° C.
471
H H H H 7-CH.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-8-methyl//
acetic acid, m.p.
160-161° C.
472
H H CH.sub.3
H 7-CH.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
4,8-dimethyl-1-ethyl//
acetic acid, m.p.
129-131° C.
473
H H CH.sub.3
H 7-CH.sub.3 O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
1,4,8-trimethyl//
acetic acid, m.p.
157-159° C.
474
H H H H 7-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-1-ethyl//
acetic acid, m.p.
168-171° C.
475
H H H H 6-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7-chloro-1-ethyl//
acetic acid, m.p.
182-183° C.
476
H H H H 6-Cl O n-C.sub.3 H.sub.7
CH.sub. 2 CO
C.sub.2 H.sub.5
7-chloro-1-propyl//
acetic acid, m.p.
182-183° C.
477
H H H H 7-C.sub.2 H.sub.5
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1,8-diethyl//acetic
acid, m.p. 145-148°
C.
478
H H H H 7-OCH.sub.3
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-8-methoxy//
acetic acid, m.p.
132° C.
479
H H H H 4-CH.sub.3
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
5,8-dimethyl-1-ethyl//
7-CH.sub.3 acetic acid, m.p.
175-176° C.
480
H H H H 4-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
5,8-dichloro-1-ethyl//
7-Cl acetic acid, m.p.
168-169° C.
481
H H H H 6-Cl O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
7,8-dichloro-1-propyl//
7-Cl acetic acid
482
H H H H 4-Cl O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
5,7-dichloro-1-methyl//
6-Cl acetic acid
483
H H H H 4-CH.sub.3
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-1-ethyl-
7-Cl 5-methyl//acetic
acid
484
H H H H 4-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
5-chloro-1-ethyl-8-
7-CH.sub.3 methyl//acetic acid
485
H H CH.sub.3
H 4-C.sub.2 H.sub.5
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7-bromo-1,5-diethyl-
6-Br 4-methyl//acetic
acid
486
H H H H 6-Cl O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
7-chloro-1,8-dimethyl//
7-CH.sub.3 acetic acid
487
H H CH.sub.3
H 4-Cl O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
1,4-dimethyl-5,7,8-
6-Cl trichloro//acetic
7-Cl acid
488
H H H H 4-OCH.sub.3
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
1-propyl-5,6,7,8-
5-OCH.sub.3 tetramethoxy//
6-OCH.sub.3 acetic acid
7-OCH.sub.3
489
H H H H 4-OCH.sub.3
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-1-ethyl-5-
7-Cl methoxy//acetic
acid
490
H H CH.sub.3
H 4-OCH.sub.3
O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
7,8-dichloro-1-
6-Cl methyl-5-methoxy//
7-Cl acetic acid
491
H H H H 4-OCH.sub.3
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-5,8-di-
7-OCH.sub.3 methoxy//acetic acid,
m.p. 167-169° C.
492
CH.sub.3
H H H 4-F O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-5-fluoro-3-
7-Cl methyl-1-propyl//
acetic acid
493
H H H H 4-F O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7,8-dichloro-5-
6-Cl fluoro-1-ethyl//
7-Cl acetic acid
494
C.sub.2 H.sub.5
H CH.sub.3
H 4-CF.sub.3
O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
3-ethyl-5-trifluoro-
7-CH.sub.3 methyl-1,4,8-
trimethyl//acetic
acid
495
H H H H 6-CF.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-7-trifluoro-
methyl//acetic acid,
m.p. 185-187° C.
496
H H CH.sub.3
H 7-CF.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-4-methyl-8-
trifluoromethyl//
acetic acid
497
H H C.sub.2 H.sub.5
H 5-CH.sub.3
O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
1,6-dimethyl-4-ethyl-
7-NO.sub.2 8-nitro//acetic acid
498
CH.sub.3
H H H 4-NO.sub.2
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-3-methyl-5-
7-Cl nitro-1-propyl//
acetic acid
499
H H H H 5-SH O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
6-mercapto-1-methyl//
acetic acid
500
H H CH.sub.3
H 7-SCH.sub.3
O CH.sub.3 CH.sub.2
C.sub.2 H.sub.5
1,4-dimethyl-8-methyl-
CH.sub.2 CO
thio//propionic acid
501
H H H H 6-SC.sub.2 H.sub.5
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-7-ethylthio//
acetic acid
502
H H H H 4-NH.sub.2 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
5-amino-1-ethyl//
acetic acid
503
H H H H 6-NH.sub.2 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7-amino-1-ethyl//
acetic acid
504
H H H H 4-SO.sub.2 NH.sub.2
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
1-propyl-5-sulfamoyl//
acetic acid
505
H H H H 6-SO.sub.2 NH.sub.2
O CH.sub.3 CH.sub.2 CO
C.sub.2 H.sub.5
1-methyl-7-sulfamoyl//
acetic acid
506
H H H H H O
##STR123##
CH.sub.2 CO
C.sub.2 H.sub.5
1-cyclopropyl//acetic
acid, m.p. 128-129°
C.
507
H H H H H O
##STR124##
CH.sub.2 CO
C.sub.2 H.sub.5
1-benzyl//acetic acid,
m.p. 139-141° C.
508
H H H H 5-F O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-6-fluoro//
acetic acid, m.p.
125-126° C.
509
H H CH.sub.3
H 6-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7-chloro-1-ethyl-
4-methyl//acetic acid
m.p. 141 -143° C.
510
H H H H 6-F O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-7-fluoro//
acetic acid, m.p.
164-166° C.
511
H H CH.sub.3
H 7-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-1-ethyl-
4-methyl//acetic acid,
m.p. 157-163° C.
512
H H CH.sub.3
H 7-C.sub.2 H.sub.5
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1,8-diethyl-4-methyl//
acetic acid, m.p.
125-130° C.
513
H H H H 7-n-C.sub.3 H.sub.7
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-8-propyl//
acetic acid, m.p.
111-114° C.
514
H H H H 7-(CH.sub.3).sub.2
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-8-isopropyl//
CH acetic acid, m.p.
165-167° C.
515
H H H H 7-n-C.sub.4 H.sub.9
O C.sub.2 H.sub.5
CH.sub. 2 CO
C.sub.2 H.sub.5
8-butyl-1-ethyl//
acetic acid, nmr
(CDCl.sub.3) δ 1.0
(t,
J=7, 6H), 6.9-7.11
(m,3H)
516
H H H H 7-sec- O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-sec-butyl-1-ethyl//
C.sub.4 H.sub.9 acetic acid, m.p.
135-137° C.
517
H H H H 7-(CH.sub.3).sub.2
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-8-isobutyl//
CHCH.sub.2 acetic acid, nmr
(CDCl.sub.3)
δ 0.9 (m, 9H),
7.0-7.5
(m,3H)
518
H H H H 7-tert- O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-tert-butyl-1-ethyl//
C.sub.4 H.sub.9 acetic acid, m.p.
169-170° C.
519
H H CH.sub.3
H 4-CH.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub. 2 H.sub.5
1-ethyl-4,5,8-trimethyl//
{ } acetic acid, m.p. 167-
7-CH.sub.3 168° C.
520
H H H H 6-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7,8-dichloro-1-ethyl//
{ } acetic acid, m.p. 112-
117° C.
521
H H H H 6-CH.sub.3 O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-chloro-1-ethyl-7-
{ } methyl//acetic acid,
7-Cl m.p. 117-120° C.
522
H H H H 6-Cl O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
7-chloro-1-ethyl-8-
{ } methyl//acetic acid,
523 7-CH.sub.3 m.p. 119-123°
H H H H 6-F O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-7-fluoro-8-
{ } methyl//acetic acid,
7-CH.sub.3 m.p. 158-160° C.
524
H H H H 7-C.sub.2 H.sub.5
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
8-ethyl-1-propyl//
acetic acid, m.p.
103-105° C.
525
H H H H 7-n-C.sub.3
O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
1,8-dipropyl//acetic
H.sub.7 acid, m.p. 109° C.
526
H H H H 6-Cl O n-C.sub.3 H.sub.7
CH.sub.2 CO
C.sub.2 H.sub.5
7-chloro-8-methyl-1-
{ } propyl//acetic acid,
7-CH.sub.3 m.p. 156-158° C.
527
H H H H
##STR125##
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-cyclopropyl-1-ethyl//
acetic acid, m.p.
153-sd,18 154° C.
528
H H H H
##STR126##
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-cyclopentyl-1-ethyl//
acetic acid, m.p. 137-
139° C.
529
H H H H
##STR127##
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
8-cyclohexyl-1-ethyl//
acetic acid, m.p. 156-
159° C.
530
H H H H
##STR128##
O C.sub.2 H.sub.5
CH.sub.2 CO
C.sub.2 H.sub.5
1-ethyl-8-phenyl// acetic
acid, m.p. 184-187°
C.
__________________________________________________________________________
Claims (17)
1. A compound of the formula Ia ##STR129## in which R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl and 2-thienyl, R2, R3, R4 and R5 are the same or different and are each selected from the group consisting of hydrogen and lower alkyl, R6a, R6b, R6c, and R6d are the same or different and selected from the group consisting of lower cycloalkyl and phenyl R7 is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, X is selected from the group consisting of oxy and thio, Y is selected from the group consisting of carbonyl, ##STR130## which each of R8, R9, R10, R11 , R12 and R13 is hydrogen or lower alkyl, and Z is selected from the group consisting of hydroxy and lower alkoxy.
2. 8-Cyclopropyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid, as claimed in claim 1.
3. 8-Cyclopentyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid, as claimed in claim 1.
4. 8-Cyclohexyl-1-ethyl-1,3,4,9-tetrahydropyrano[3,4-b]-indole-1-acetic acid, as claimed in claim 1.
5. 1-Ethyl-8-phenyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid, as claimed in claim 1.
6. A method of treating inflammation in a warm-blooded animal, comprising: administering perorally to said animal an antiinflammatorily effective amount of the compound of the following formula Ib ##STR131## in which R1 is selected from the group consisting of lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl and 2-thienyl, R2, R3, R4 and R5 are the same or different and are each selected from the group consisting of hydrogen and lower alkyl, R6a, R6b, R6c, and R6d are the same or different and selected from the group consisting of hydrogen, lower alkyl, lower cycloalkyl, hydroxy, lower alkoxy, benzyloxy, lower alkanoyloxy, phenyl, nitro, halo, mercapto, lower alkylthio, trifluoromethyl, amino and sulfamoyl, R7 is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl, X is selected from the group consisting of oxy and thio, Y is selected from the group consisting of carbonyl, ##STR132## which each of R8, R9, R10, R11, R12 and R13 is hydrogen or lower alkyl, and Z is selected from the group consisting of hydroxy and lower alkoxy.
7. A method of producing analgesia in a warm-blooded animal, comprising: administering perorally to said animal an analgesically effective amount of the compound of formula 1b of claim 6.
8. A pharmaceutical composition comprising: an anti-inflammatory effective amount of the compound of formula 1b of claim 6 and a pharmaceutically acceptable carrier.
9. A pharmaceutical composition, comprising: an analgesically effective amount of the compound of Formula 1b of claim 6 and a pharmaceutically acceptable carrier.
10. A method according to claim 6 wherein 1-propyl-1,3,4,9,tetrahydropyrano[3,4-b]indole-1-acetic acid is the compound administered.
11. A method according to claim 6 wherein 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid is the compound administered.
12. A method according to claim 7 wherein 1-propyl-1,3,4,9,tetrahydropyrano[3,4-b]indole-1-acetic acid is the compound administered.
13. A method according to claim 7 wherein 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid is the compound administered.
14. A pharmaceutical composition according to claim 8 wherein the compound of Formula 1b is 1-propyl-1,3,4,9,-tetrahydropyrano[3,4-b]indole-1-acetic acid.
15. A pharmaceutical composition according to claim 8 wherein the compound of Formula 1b is 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid.
16. A pharmaceutical composition according to claim 9 wherein the compound of Formula 1b is 1-propyl-1,3,4,9,tetrahydropyrano[3,4-b]indole-1-acetic acid.
17. A pharmaceutical composition according to claim 9 wherein the compound of Formula 1b is 1,8-diethyl-1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ZA72/3344 | 1972-05-16 | ||
| ZA723344A ZA723344B (en) | 1971-06-01 | 1972-05-16 | Indole derivatives |
| US05/555,506 US4012417A (en) | 1972-05-16 | 1975-03-05 | Process for preparing pyrano[3,4-b]indole or thio pyrano[3,4-b]indole derivatives |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/555,506 Division US4012417A (en) | 1972-05-16 | 1975-03-05 | Process for preparing pyrano[3,4-b]indole or thio pyrano[3,4-b]indole derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4076831A true US4076831A (en) | 1978-02-28 |
Family
ID=27070906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US05/749,931 Expired - Lifetime US4076831A (en) | 1972-05-16 | 1976-12-13 | Pyrano[3,4-b]-indole derivatives, pharmaceutical compositions and methods of use |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4076831A (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4118394A (en) * | 1976-10-18 | 1978-10-03 | Ayerst, Mckenna & Harrison Limited | Pyrano- and thiopyranoindole derivatives |
| US4188326A (en) * | 1975-09-08 | 1980-02-12 | Warner-Lambert Company | Indolopyrones having anti-allergic activity |
| US4670462A (en) * | 1986-03-11 | 1987-06-02 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids |
| US4677132A (en) * | 1986-03-12 | 1987-06-30 | American Home Products Corporation | Inhibition of bone resorption by etodolac |
| US4775690A (en) * | 1987-01-13 | 1988-10-04 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids |
| EP0221032A3 (en) * | 1985-10-25 | 1988-10-05 | Farmaka S.R.L. | Sodium salt of etodolic acid and process for its preparation |
| US4826994A (en) * | 1986-03-11 | 1989-05-02 | American Home Products Corporation | Production of substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids |
| US4960902A (en) * | 1988-08-19 | 1990-10-02 | American Home Products Corporation | Trifluoromethoxy substituted 1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids |
| US4971960A (en) * | 1986-03-11 | 1990-11-20 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids |
| US5128363A (en) * | 1988-08-19 | 1992-07-07 | American Home Products Corporation | Trifluoromethoxy substituted 1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids |
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| US6964979B2 (en) | 2002-05-21 | 2005-11-15 | Wyeth | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
| US20060058532A1 (en) * | 2004-09-10 | 2006-03-16 | Warren Chew | Process for the scalable synthesis of 1,3,4,9-tetrahydropyrano[3,4-b]-indole derivatives |
| US7217730B2 (en) | 2002-05-21 | 2007-05-15 | Wyeth | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939178A (en) * | 1971-06-01 | 1976-02-17 | American Home Products Corporation | Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles |
-
1976
- 1976-12-13 US US05/749,931 patent/US4076831A/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939178A (en) * | 1971-06-01 | 1976-02-17 | American Home Products Corporation | Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4188326A (en) * | 1975-09-08 | 1980-02-12 | Warner-Lambert Company | Indolopyrones having anti-allergic activity |
| US4118394A (en) * | 1976-10-18 | 1978-10-03 | Ayerst, Mckenna & Harrison Limited | Pyrano- and thiopyranoindole derivatives |
| EP0221032A3 (en) * | 1985-10-25 | 1988-10-05 | Farmaka S.R.L. | Sodium salt of etodolic acid and process for its preparation |
| US4826994A (en) * | 1986-03-11 | 1989-05-02 | American Home Products Corporation | Production of substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids |
| US4670462A (en) * | 1986-03-11 | 1987-06-02 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-B)indole-1-acetic acids |
| US4971960A (en) * | 1986-03-11 | 1990-11-20 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids |
| US4677132A (en) * | 1986-03-12 | 1987-06-30 | American Home Products Corporation | Inhibition of bone resorption by etodolac |
| US4775690A (en) * | 1987-01-13 | 1988-10-04 | American Home Products Corporation | Substituted 1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acids |
| US4960902A (en) * | 1988-08-19 | 1990-10-02 | American Home Products Corporation | Trifluoromethoxy substituted 1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids |
| US5128363A (en) * | 1988-08-19 | 1992-07-07 | American Home Products Corporation | Trifluoromethoxy substituted 1,3,4,9-tetrahydropyrano-[3,4-b]indole-1-acetic acids |
| US6106862A (en) * | 1998-08-13 | 2000-08-22 | Andrx Corporation | Once daily analgesic tablet |
| US6177102B1 (en) | 1998-08-13 | 2001-01-23 | Andrx Pharmaceuticals, Inc. | Once daily analgesic tablet |
| US6964979B2 (en) | 2002-05-21 | 2005-11-15 | Wyeth | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
| US7217730B2 (en) | 2002-05-21 | 2007-05-15 | Wyeth | Method for the use of pyranoindole derivatives to treat infection with Hepatitis C virus |
| US20060058532A1 (en) * | 2004-09-10 | 2006-03-16 | Warren Chew | Process for the scalable synthesis of 1,3,4,9-tetrahydropyrano[3,4-b]-indole derivatives |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3974179A (en) | 1,3,4,9-Tetrahydropyrano[3,4-b]indole-1-acetamides and derivatives | |
| US3939178A (en) | Certain pyrano [3,4-b]indoles and thiopyrano[3,4-b]indoles | |
| US3843681A (en) | 1-carboxamido pyrano(thiopyrano)(3,4-6)indole derivatives | |
| US4076831A (en) | Pyrano[3,4-b]-indole derivatives, pharmaceutical compositions and methods of use | |
| US5288743A (en) | Indole carboxylate derivatives which inhibit leukotriene biosynthesis | |
| JP2556821B2 (en) | Tricyclic aromatic compound | |
| US4133814A (en) | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents | |
| AU690140B2 (en) | Carbocyclic and heterocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents | |
| US3682930A (en) | 4(1-alkyl-4-piperidylidine)-4h-benzo {84,5{9 {0 cyclohepta {8 1,2{14 6{9 | |
| US4012417A (en) | Process for preparing pyrano[3,4-b]indole or thio pyrano[3,4-b]indole derivatives | |
| EP0248523B1 (en) | Pyrazoles | |
| US4021451A (en) | Process for preparing polycyclic heterocycles having a pyran ring | |
| US4070371A (en) | Derivatives of 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid | |
| JPH0588232B2 (en) | ||
| CZ283965B6 (en) | 2-thioindoles, 2-indolinethiones and polysulfides, their selenium analogs and pharmaceutical preparations based thereon | |
| US4041169A (en) | Pharmaceutical method for using pyrano-and thiopyranoindole derivatives | |
| US5491152A (en) | Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis | |
| US4036842A (en) | Process for preparing polycyclic heterocycles having a pyran ring | |
| US4537892A (en) | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | |
| US4695571A (en) | Tricyclic oxindole antiinflammatory agents | |
| US4864028A (en) | Spiro-tricyclicaromatic succinimide derivatives | |
| US5153211A (en) | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase | |
| US4695581A (en) | 2-(3,5-dialkyl-4-hydroxyphenyl)indole derivatives | |
| US3010971A (en) | Cyclopropylamine derivatives and processes for their preparation | |
| HU206204B (en) | Process for producing benzopyranol derivatives and pharmaceutical compositions comprising same as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PTEF | Application for a patent term extension |
Free format text: PRODUCT NAME: LODINE (ETODOLAC); REQUESTED FOR 2 YEARS Filing date: 19910311 Expiry date: 19950228 |
|
| PTEG | Grant of a patent term extension |
Free format text: PRODUCT NAME: LODINE (ETODOLAC) Filing date: 19910311 Expiry date: 19950228 Extension date: 19970227 |